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ABSTRACT 
 
Ribonuclease P (RNase P) catalyzes the 5ʼ maturation of precursor-tRNA 
(pre-tRNA). Bacterial RNase P is composed of a catalytic RNA subunit (P RNA) 
and one small protein subunit (P protein); both subunits contribute to substrate 
recognition. Previous studies suggest that RNase P recognizes the tertiary fold of 
the tRNA moiety and the leader of pre-tRNA interacts with the P protein subunit. 
Bioinformatics analyses of 5ʼ leader sequences in 160 bacterial genomes 
demonstrated species-dependent sequence preferences near the pre-tRNA 
cleavage site, suggesting the formation of sequence-specific interactions with the 
5ʼ leader. Here we demonstrate that the affinity of Bacillus subtilis RNase P for 
pre-tRNAAsp is modulated by the leader sequence; pre-tRNAAsp with adenosine 
and uracil at the N(-2) and N(-3) positions in the leader, respectively, have the 
highest binding affinity. Mutagenesis data indicate that a non-conserved 
nucleotide, G319 at J18/2 of the P RNA, forms a trans Watson-Crick-sugar-edge 
interaction with the base at N(-2) of pre-tRNA. Additionally, N61, R62 and R65 
residues at the “RNR” motif of the P protein indirectly affect the N(-3) sequence 
selectivity.  Sequence alterations at the N(-3) nucleotide also modulate the Ca2+-
dependence of pre-tRNA affinity, suggesting that interactions with this nucleotide 
stabilize the active conformation of RNase P.  
 xi 
    The newly identified human mitochondrial (mtRNase P) and chloroplast RNase 
P are “proteinaceous” RNase P enzymes that are proposed to consist of three 
(MRPP1, MRPP2 and MRPP3) and one (PRORP1) protein subunits, respectively. 
MRPP3 is homologous to the PRORP1 protein. Sequence alignments of MRPP3 
homologs indicate eight conserved residues, including cysteine, aspartate and 
histidine residues, located in the C-terminal domain, which have been proposed 
to coordinate catalytic and/or structural metal ions. Here, we demonstrate that 
the MRPP3 subunit is catalytically active alone in vitro, and thereby is the 
catalytic subunit of the human mtRNase P. Introducing the MRPP1 and MRPP2 
subunits to MRPP3 subunit moderately reduces the human mtRNase P catalytic 
activity. Furthermore, two essential metal ions have been identified in MRPP3, 
including a minimum of one Mg2+ that activates catalysis and a tightly bound zinc 
ion that could serve to stabilize the structure of MRPP3 required for catalysis.  
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CHAPTER 1 
 
INTRODUCTION 
 
    The biogenesis of tRNA requires a complex set of processing events to 
convert the primary transcript precursor tRNA (pre-tRNA) to a mature functional 
tRNA (2). Mature tRNA is required by all organisms and plays an integral role in 
translation by carrying amino acids to the ribosome to make protein. The 
maturation of the pre-tRNA consists of removal of both the 5’ and 3’ termini of the 
RNA chain (Figure 1-1). Maturation of the 3’ terminus of pre-tRNA in bacteria 
varies from species to species. In Escherichia coli (E. coli), at least five different 
endo- and exonucleases (RNase II, D, PH, BN, and T) are involved, while in 
Bacillus subtilis (B. subtilis) only a single endonuclease (RNase Z) is required to 
catalyze the maturation of the 3’ terminus of pre-tRNA (3-5). Eukaryotes from 
Drosophila to humans also utilize tRNase Z to catalyze the 3’ end maturation of 
pre-tRNA (6-8). However, the maturation of 5’ terminus of pre-tRNA requires only 
a single enzyme, called ribonuclease P (RNase P), and this is the only conserved 
enzyme in the pre-tRNA maturation pathway (9-11).  
RNase P is a ribonucleoprotein complex that catalyzes the 5’ end maturation of 
pre-tRNA to form mature tRNA and 5’ leader. RNase P is conserved in all 
domains of life but the composition of RNase P varies from Bacteria, to Achaea 
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and Eucarya (12-14). Most known RNase Ps have a single large catalytic RNA  
(~130 kDa, P RNA) component that associates with either one, ≥four and ≥nine 
proteins in Bacteria, Achaea and Eukarya, respectively. In the presence of high 
monovalent salt and magnesium concentrations, bacterial and some archeal P 
RNAs are catalytically active in vitro in the absence of P protein (15,16). In 
addition, some eukaryal P RNAs, such as Homo sapiens P RNA, have been 
suggested to have some catalytic activity in vitro (17). However, recent studies 
have demonstrated that RNase P in certain organelles, including human and 
Arabidopsis thaliana mitochondria, consists of only protein subunits (18,19). 
These protein-based organellar RNase P enzymes carry out a similar function as 
the RNA-based RNase P enzyme. It is of great interest to understand how a 
“proteinaceous RNase P” evolved to retain the catalytic and structural roles of the 
RNA-mediated RNase P. 
 
 
 
 
Figure 1-1: Model of pre-tRNA maturation pathway adapted from Hartmann R.K. 
et. al., 1999 (1). The mature tRNA is shown in black, while the 5’ leader, 3’ trailer 
and intervening sequences are in grey. 
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Bacterial RNase P 
Structure of RNase P RNA 
 
     Bacterial RNase P RNA is encoded by the rnpB gene and is 300 to 400 
nucleotides long. Based on phylogenetic comparative analysis, bacterial P RNA 
shows significant secondary structure diversity and has little sequence 
conservation among the 300 to 400 nucleotides (20). The secondary structure of 
the bacterial P RNA is broadly grouped into two archetypes, type A (ancestral-
like) represented by E. coli and type B (Bacillus-like) represented by B. subtilis. 
X-ray crystal structures of both the type A (from Thermotoga maritima) and B 
(from Bacillus stearothermophilus) P RNAs have been solved (21,22). Both the 
type A and B P RNAs have a common core structure that is highly conserved in 
all three domains of life, including two independently folding domains, termed the 
specificity (S), and catalytic (C) domains (Figure 1-2). The conserved core 
structure of the S-domain is a non-helical structure that consists of the J11/12 
and J12/11 connectors and the P9, P10 and P11 stems. The conserved core 
structure of the C-domain includes the coaxial stacks of P1/P4/P5, P2/P3 and 
P8/P9 (23). In the conserved core structures of the S and C-domains in bacterial 
P RNA, about half of the nucleotides are conserved.  
    Hydroxyl radical footprinting, crosslinking and affinity cleavage experiments 
illustrate that the C-domain of the B. subtilis P RNA contacts and forms a specific 
complex with the P protein, which is consistent with the crystal structure of T. 
maritima RNase P complex (24-27). This C-domain-P protein complex able to 
cleave the single stranded RNA and hairpin loop 3’ end with similar efficiency as 
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the B. subtilis RNase P holoenzyme, suggesting that the active site is located at 
the C-domain of the P RNA (24). However, B. subtilis RNase P holoenzyme 
binds and cleaves pre-tRNA 100- to 500-fold better than the C-domain-P protein 
complex, indicating that the S-domain of the P RNA contributes to the pre-tRNA 
specificity and affinity (24). 21 of about 200 nucleotides in the universal core of all 
known P RNA sequences are conserved and situated at the J3/4-P4-J2/4, J15/2 
and J11/12-J12/13 (Figure 1-3A) (28). Eleven of the 21 conserved nucleotides 
are located within helix P4, suggesting that the conserved nucleotides in helix P4 
play important structural and/or functional roles in RNase P catalysis (20). 
Furthermore, the E. coli and B. subtilis RNase Ps are able to interchange their P 
protein subunits while retaining some catalytic activity in vitro (15). These results 
suggest that bacterial P RNAs retain a similar tertiary structural and the region of 
P RNA-P protein contacts is highly conserved (Figure 1-3B). 
Figure 1-2:  Crystal structures of bacterial RNase P RNAs adapted from 
Kazantsev, A.V. et. al., 2005 and Torres-Larios, A. et. al., 2005 (21,22). (A) T. 
maritima and (B) B. stearothermophilus P RNAs. The catalytic domain of P RNA 
is highlighted with red, orange and cyan stems. The specificity domain is 
highlighted with green, brown and blue stems. 
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Figure 1-3: Secondary structure of T. maritima RNase P RNA adapted from 
Reiter, N.J. et. al., 2010 (22,25). (A) Sequences that are conserved in all known 
bacterial P RNAs are shown in capital letters (20). The C-domain of T. maritima 
P RNA includes P2/P3, P1/P4/P5, P15/16, P17 and P18 which are shown in 
green, blue, yellow and purple, respectively. The S-domain of the T. maritima P 
RNA consists of P8/P9, P10, P11, P12 and P13/14 which are colored green, 
orange and pink, correspondingly. (B) Proposed sites of the P RNA contacts with 
the pre-tRNA and P protein based on the biochemical and crosslinking data as 
well as the recent crystal structural of the T. maritima RNase P.tRNA and RNase 
P.5’ leader complex (25,26). The P RNA contacts with mature tRNA, 5’ leader, 
3’CCA and P protein are highlighted with in pink, orange, green and light blue, 
respectively.   
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Indeed, based on the crystal structure of T. maritima RNase P, the region where 
P RNA contacts P protein is conserved in all bacterial species (25).  
Structure of RNase P Protein 
 
    Bacterial RNase P is composed of only a single small P protein (~14 kDa) that 
associates with P RNA (130 kDa), which makes bacterial RNase P the simplest 
system for studying structure and function (29,30). Phylogenetic comparison 
analysis indicates low sequence similarity between the ancestral-like (type A) 
and Bacillus-like (type B) P proteins (31,32). However, X-ray crystal structures of 
P protein indicate a structural similarity between the homologous type A (from T. 
maritima) and type B (from B. subtilis and S. aureus) P proteins (33-35). Both 
type A and type B P proteins adopt an α-β sandwich fold with a topology 
αβββαβα and have a highly conserved surface charge. There are three potential 
RNA binding motifs in the bacterial P protein, including an unusual βαβ crossover, 
a central β-cleft formed by four anti-parallel β strands flanked by an α-helix, and a 
putative  “metal binding” loop (Figure 1-4). The βαβ crossover has a sequence 
termed the RNR motif (RNRXKRXXR) that binds proximal to the highly 
conserved elements of the helix P4 of P RNA, which is proposed to form the 
enzyme’s active site (26,36). 
    Although the P protein does not play a direct role in catalysis, it is required for 
in vivo function of RNase P. Binding studies indicate that the P protein enhances 
the affinity of RNase P for pre-tRNA by 104 fold and increases the magnesium 
affinity of the RNase P.pre-tRNA complex (37,38). Cross-linking and time-
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resolved fluorescence resonance energy transfer (trFRET) experiments have 
demonstrated that the central β-cleft of the P protein is located near the 5’ leader 
from the third to the seventh nucleotide away from the cleavage site (27,39), 
consistent with the recent structure of the RNase P-tRNA-5” leader complex (25). 
The affinity of the RNase P.pre-tRNA complex for Mg2+ ions increases by > 2-fold 
as the 5’ leader lengthens from 2 to 5 nucleotides, indicating that the P protein 
also enhances the Mg2+ binding site in the RNase P.pre-tRNA complex (40). 
Moreover, the highly conserved “RNR” sequence motif stabilizes the active 
conformation of RNase P by augmenting the affinity of the P protein for the P 
RNA by > 20-fold (41). The side chains in the RNA motif also increase the affinity 
of RNase P for pre-tRNA and reduce the concentration of metal ions required for 
RNase P catalysis in vitro (41,42).  
    Hartmann and coworkers also demonstrated that deletion of the B. subtilis P 
protein inhibits cell growth, however, substitution with other bacterial P proteins 
including those from Aquificae, Bacteroidetes, Cyanobacteria, α-Proteobacteria, 
β-Proteobacteria and γ-Proteobacteria, is able to rescue cell growth (43). 
Additionally, deletion of the α1 helix from B. subtilis P protein causes growth 
defects while deletion of the α3 helix impairs the cells vitality. Although the 
bacterial P proteins have < 30% sequence identity, replacement B. subtilis P 
protein by other bacterial RNase P proteins can rescue cells growth, suggesting 
that the bacterial P proteins have similar tertiary structures and are able to form 
functional heterologous RNase P in vivo. The β-central cleft of the P protein is 
flanked by the α1 helix, which cross-linked to the 5’ leader of the pre-tRNA 
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(26,27). Therefore, deletion of the α1 helix could affect the pre-tRNA recognition 
by the RNase P in vivo and cause growth defects in cells. The α2 and α3 helices 
form a hydrophobic core with the interior of the β-central cleft, which could be 
crucial for P protein folding and structure stabilization. Therefore, deletion of the 
α3 helix could compromise the structure stability of P protein and impair the 
formation of RNase P holoenzyme complex and thereby inhibit cell growth. 
These results indicate that the P protein-pre-tRNA and P RNA-P protein 
interactions are important for enhancing the binding affinity of the RNase P.pre-
tRNA complex for substrate and Mg2+ ions. 
pre-tRNA Substrate Recognition 
 
    pre-tRNA is the primary substrate for RNase P which catalyzes hydrolysis to 
form a 5’ phosphate and a 3’ hydroxyl group (Figure 1-5) (15). However, RNase 
P is also capable of recognizing and cleaving multiple small, stable RNA 
molecules, termed non-tRNA substrates. For example, RNase P derived from 
E.coli catalyzes cleavage of precursor 4.5S RNA (pre-4.5S), and the intergenic 
region of polycistronic operon mRNAs (his, tna and secG) in vitro (15,44). 
Biochemical data indicate that the B. subtilis RNase P recognizes T stem-loop 
and acceptor stem of the pre-tRNA through coaxial stacking and backbone 
contacts with the S-domain of the P RNA (45-47). This interaction is mediated 
through the tertiary structure of the pre-tRNA (Figure 1-6). The crystal structure 
of the T. maritima RNase P.tRNA complex indicates that the S-domain of the P 
RNA base stacks with the TΨC and D loops of the pre-tRNA, consistent with the 
biochemical data (25). Moreover, B. subtilis RNase P holoenzyme binds pre-
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tRNA 100-fold better than C-domain-P protein complex (24). These results 
suggest that contacts between the S-domain and the T-stem loop and acceptor 
stem enhance the specificity and affinity of the pre-tRNA for RNase P.  
 
Figure 1-4: Structure of isolated bacterial RNase P proteins in contact with the 5’ 
leader of the pre-tRNA. The “RNR” motif is highlighted in magenta, while the 5’ 
leader of pre-tRNA highlighted in blue. (A) Crystal structure of the T. maritima P 
protein in contact with the 5’ leader is adapted from Reiter, N.J. et. al., 2010  
(25,33). Based on the crystal structure, the residues R52 and K56 contacts with 
the N(-1) nuceotide, the K51 contact with the N(-4) and N(-5) nucleotides, the 
F17 contact with N(-3) and N(-4) nucleotides and the F21 contact with N(-4) 
nucleotide. The distance between the P protein and the 5’ leader contacts is ≤  ~ 
4.5 Å.  (B) The B. subtilis P protein in contact with the 5’ leader (in red) based on 
trFRET data of the P RNA-P protein-pre-tRNA complex in Ca2+ buffers (48,49). 
Biochemical data have shown that N(-4) forms a direct contact with Y34 and 
stacks with F20. The F16, F20, K52, K53, N56, R60, N61 and R62 residues of B. 
subtilis P protein are corresponded to the F17, F21, K51, R52, K56, R60, N61 
and K62 residues of T. maritima P protein. 
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Figure 1-5: Schematic diagram of proposed cleavage reaction of the pre-tRNA 
by bacterial RNase P. 
 
RNase P also recognizes pre-tRNA substrates through contacts with the 
CCA at the 3’ end and with the 5’ leader (50-52). The 3’ RCCA motif forms a 
canonical Watson-Crick base pair with the G292, G293 and U294 from the P15 
strand of the E. coli M1 RNA, consistent with the crystal structure of T. maritima 
RNase P.tRNA complex (53). The 3’ end separates from the 5’ end of the tRNA 
to enter a 20 Å tunnel pseudoknot formed by the P6/L17 of the P RNA (25).  
However, not all pre-tRNA transcripts encode the 3’ RCCA; the tRNA 
nucleotidyltransferase catalyzes addition of CCA to many tRNAs (54,55).   
  Fierke and coworkers illustrated that the RNase P holoenzyme has a 
higher binding affinity and cleavage rate for pre-tRNA relative to tRNA that is 
dependent on the leader length; this preference is not observed for the P RNA 
subunit alone (37,39,48). These data suggest that the P protein enhances the 
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affinity and catalytic efficiency of the RNase P for pre-tRNA by interacting with 
the 5’ leader. Harris and coworkers have demonstrated that this interaction with 
the 5’ leader is important for the uniform binding affinity of E. coli RNase P for all 
pre-tRNAs, regardless of the sequence variation of the pre-tRNA; suboptimal 
tRNA sequences with decreased binding affinity for RNase P are compensated 
by a higher affinity interaction with the 5’ leader (56). Similar phenomena are 
observed in the uniform substrate binding by the elongation factor Tu (57).  
Furthermore, crosslinking and trFRET data from B. subtilis RNase P as well as a 
recent crystal structure of the T. maritima RNase P.5’ leader complex illustrate 
that the 5’ leader of the pre-tRNA is located near the P RNA/P protein interface 
as well as at the central β-cleft of the P protein (25,27,39,51) (Figure 1-4). 
However, details of the molecular interaction between the 5’ leader and RNase P 
are not fully elucidated.  Thus, in Chapter 2 we analyze the molecular recognition 
of the 5’ leader by the B. subtilis RNase P. 
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Figure 1-6: Tertiary and secondary structure of pre-tRNA. (A) Tertiary structure 
of canonical pre-tRNA with mature tRNA in cyan and 5’ leader in green (25,58). 
(B) Secondary structure of the B. subtilis pre-tRNAAsp with 5’ leader highlighted in 
orange, 3’ end of the CCA in green, acceptor stem in light blue and T-stem-loop 
in red (46,52,59,60). These pre-tRNA regions are essential substrate recognition 
by the bacterial RNase P. 
 
Metal-dependent Catalysis of the RNase P 
    Bacterial RNase P is a metal-dependent enzyme that catalyzes the maturation 
of pre-tRNA in the presence of Mg2+ ions in vitro (61). The P RNA subunit 
catalyzes pre-tRNA cleavage in the presence of high concentration of 
monovalent and divalent ions (15). Cations play a crucial role in the RNase P 
catalysis by stabilizing the P RNA and pre-tRNA structures and enhancing the 
affinity of the P RNA for pre-tRNA.  Divalent cations capable of inner sphere 
coordination are essential for stabilizing the transition state for pre-tRNA 
cleavage (62,63). Thus far, the specific Mg2+ ion binding sites that are essential 
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for RNase P catalysis are not clearly elucidated. Identification of specific Mg2+ 
ions binding sites is complicated by the large number of nonspecific Mg2+ ions 
(>100 ions) that interact with P RNA through Coulombic contacts.  These cations 
stabilize the P RNA structure.  
    A highly conserved helix, P4, in P RNA has been proposed to contain specific 
Mg2+ binding sites important for catalysis. Eleven out of 21 conserved 
nucleotides in P RNA are located in helix P4 and deletion of this helix abrogates 
the catalytic activity of the RNase P (64-66).  Sulfur substitution at the 
nonbridging oxygens of the phosphodiester bonds (phosphorothioate 
substitution) at A49 and U50 in helix P4 decreases the cleavage rate of the B. 
subtilis RNase P by 500-15000 fold in the presence of Mg2+, without affecting 
pre-tRNA affinity. However, the catalytic activity of the B. subtilis RNase P is 
partially rescued by the addition of the manganese ions. The recent crystal 
structure of the T. maritima RNase P.tRNA complex illustrates that the 5’ end of 
tRNA interacts with nucleotides in P4 (A49, A50, G51, U52) and heavy metal 
derivatives suggest that two Mg2+ binding sites are located in the helix P4; one 
interacts with the phosphodiester oxygens at A49/A50 and the other binds near 
the base of the bulged U52 (25). NMR and XAS data of metal binding to a stem-
loop model of B. subtilis helix P4 identify an inner-sphere metal binding site 
formed by the bases of G378 and G379 (67,68). Nucleotide analog interference 
mapping (NAIM) data suggest that one or more Mg2+ binding site(s) important for 
function is clustered at the P1-P4 multihelix junction of E. coli RNase P (69). The 
Mg2+ ion bound to helix P4 have been proposed to function either as a metal-
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hydroxide nucleophile to catalyze RNase P cleavage or as a cocatalytic metal ion 
that stabilizes the active P RNA conformation (68,70). Additionally interactions 
between helix P4 of P RNA and the RNR motif of P protein enhances the affinity 
of the Mg2+ binding site, as described previously, to facilitate RNase P catalysis 
at physiological metal ion concentrations. 
 
Human Mitochondrial RNase P (mtRNase P) Protein Complex  
 
    The human mitochondrial genome is a single, closed circular DNA molecule of 
16 kb (71). Except for a 1 kb non-coding region, the mitochondrial DNA (mtDNA) 
genome is tightly with packed with 37 genes, including 13 subunits of oxidative 
phosphorylation enzymes, mitochondria-specific tRNA and rRNA (72). Unlike the 
nuclear genome where RNA is frequently transcribed one gene at a time, mtDNA 
is transcribed into three long polycistronic RNA chains. This transcript is 
proposed to be cleaved by one or more endonucleases to release functional 
mRNA, rRNA and tRNA (73). Human mtDNA contains 22 tRNA genes that are 
dispersed through the genome and are transcribed into polycistronic RNA chains 
containing rRNA and protein-coding mRNA (74,75). Therefore, cleavage of tRNA 
genes from the primary transcript could also release mature mRNA and rRNA 
and be an important step in mitochondria biogenesis. Recently, two of the 
enzymes essential for tRNA processing in the human mitochondrial have been 
discovered:  tRNase Z catalyzes the 3’ end maturation of pre-tRNA in vivo and 
RNase P catalyzes the 5’ end maturation of pre-tRNA (6,19).  
Mutations in human mtRNase P and (mt)pre-tRNA have been associated 
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with numerous diseases, such as MELAS (mitochondrial myopathy, 
encephalopathy, lactic acidosis and stroke-like symptoms), progressive external 
opthalmoplegia and/or diabetes and coronary artery disease (76,77). Hence, 
investigating the structure and function of (mt)RNase P will provide insight into 
the role of tRNA biogenesis in dysfunctional mitochondria diseases. 
    Identification of the genes encoding human mitochondrial RNase P (mtRNase 
P) has been a great challenge because this enzyme has no sequence homology 
to the RNA-dependent RNase P found in Bacteria, Archaea and Eukarya.  
Furthermore, this enzyme is encoded by the nuclear genome rather than the 
mitochondrial genome (78). Initial biochemical experiments demonstrated the 
existence of two different RNase P enzymes in human cells with different 
properties (79). The human mtRNase P catalyzes cleavage of the mitochondrial 
substrates ((mt)pre-tRNATyr and (mt)pre-tRNALeu) but not human nuclear 
substrates ((n)pre-tRNASer), while the human nuclear RNase P catalyzes 
cleavage of (n)pre-tRNASer and (mt)pre-tRNALeu but not (mt)pre-tRNATyr. Many of 
the human (mt)pre-tRNAs have primary sequences and tertiary structures that 
deviate from the canonical cytoplasmic and bacterial tRNAs (80,81). Therefore, 
the mode of substrate recognition by the human mtRNase P could be different 
from the nuclear RNase P. However, (mt)pre-tRNALeu is cleaved by both 
mtRNase P and nuclear RNase P, presumably because this tRNA contains 
features from both the mitochondrial and cytoplasmic tRNAs. These biochemical 
data suggest that nuclear RNase P and mtRNase P are two distinct enzymes 
that have different but overlapping substrate specificity.   
 17 
    Density gradient centrifugation data also demonstrate that human mtRNase P 
has a protein-like density of 1.23 mg/mL, which differs from the E. coli RNase P, 
a ribonucleoprotein that has a density-like between RNA and protein  (1.55 
mg/mL) (82). Furthermore, the human mtRNase P activity is insensitive to 
micrococcal nuclease treatment that inactivates nuclear RNase P, suggesting 
that the human mtRNase P could be a “protein only” RNase P enzyme (79,82). 
Recently, Rossmanith and coworkers have successfully isolated proteins that 
catalyze mitochondrial pre-tRNA cleavage; they propose that the human 
mtRNase P is composed of an assembly of three protein subunits, without an 
RNA moiety (19). Partial purification, identification of protein subunits by mass 
spectrometry and reconstitution of the activity from recombinant subunits were 
employed to identify the human mtRNase P. The three different protein subunits 
proposed to form human mtRNase P, called MRPP1, MRPP2 and MRPP3, 
reconstitute to catalyze the 5’ end maturation of the pre-tRNA.  
RNA (guanine-9-)methyltransferase domain containing 1, MRPP1 
 
    RNA (guanine-9-) methyltransferase domain containing 1, termed MRPP1 in 
the human mtRNase P complex, is encoded by the RG9MTD1 gene on 
chromosome 3, has a molecular mass of ~46 kDa and contains an N-terminal 
mitochondrial localization sequence (19). MRPP1 is homologous to a yeast tRNA 
m1G methyltransferase, Trm10p, that catalyzes the N1 methylation of guanosine 
at position 9 of tRNA. Trm10p utilizes S-adenosylmethionine (SAM) as a methyl 
donor for this reaction (83). Based on the sequence homology with Trm10p, 
MRPP1 is proposed to function as a m1G9 methyltransferase as well. 
 18 
Unpublished data from the Rossmanith laboratory suggest that MRPP1 catalyzes 
the methylation of G9 of human (mt)tRNAs ((19), unpublished data).  However, 
SAM is not an essential cofactor for cleavage of (mt)pre-tRNATyr catalyzed by 
mtRNase P, suggesting that methylation is not the sole function of this subunit. 
   To date, most known eukaryotic tRNA sequences have a purine at position 9, 
with the exception of four tRNAGlu from Arabidopsis thaliana, one tRNAArg from 
Caenorhabditis elegans, two tRNAHis from Homo sapiens and one tRNAGlu from 
Plasmodium falciparum (84). In yeast, 23 out of 34 tRNAs have guanosine at 
position 9. However, only 10 of these tRNAs contain the m1G9 modification in 
vivo (83). Trm10p orthologs from the archeal Sulfolobus Acidocaldarius 
(Saci_1677p) and Thermococcus kodakaraensis (TK0422p) also methylate 
adenosine and guanosine at position 9 of the tRNA (85). The yeast data indicate 
that a guanosine at position 9 of tRNA is not the defining recognition element for 
catalysis of the m1G9 modification. The crystal structure of yeast tRNAPhe 
visualizes the formation of a reverse-Hoogsteen-non-Watson-Crick base-triple 
interaction between the A at position 9 and U12-A23 (86). It is possible that 
methylation of the nucleotide at position 9 of tRNA could be related to tRNA 
structure.  
    MRPP1, Trm10p and the Saci_1677p and TK0422p orthologs belong to the 
SAM-dependent tRNA methyltransferase (MTase) family. These MTases 
possess a fold similar to the Rossmann fold and are therefore called Rossmann 
fold MTases. This family of enzymes has been classified into five different 
classes based on their distinct structural features. Sequence homology indicates 
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that the archaeal Saci_1677p and TK0422p MTases belong to the SPOUT 
superfamily that is part of the class IV MTases (85). This class of MTases has a 
Rossmann fold consisting of a six-stranded β sheet core flanked by seven α 
helices (87-90). Arabidopsis thaliana fibrillarin, a nucleolar protein that involved in 
pre-rRNA and 2’-O-ribose methylation of rRNA and snRNAs, is part of the 
Rossmann fold SAM-dependent MTases family (91). Fibrillarin has two RNA 
binding sites that have Rossmann folds and mutation at the RNA binding site 
decrease the binding affinity for the U3 snoRNA and TMV RNA by > 5-fold, 
suggesting that Rossmann fold is involved in the RNA binding (91). Although 
MRPP1 is not yet classified due to the lack of high resolution structural 
information, sequence homology indicates that MRPP1 belongs to the MTase 
family and could contain a Rossmann fold that functions as a RNA-binding 
domain. Therefore, MRPP1 has been proposed to contain an RNA-binding 
domain that contributes to the substrate recognition of the mtRNase P complex. 
Furthermore, it has been suggested that m1G modification by MRPP1 could be a 
novel type of substrate recognition by mtRNase P complex (19,78).  
Hydroxysteroid (17-β) dehydrogenase 10, MRPP2 
 
    MRPP2 has also been identified as hydroxysteroid (17-β) dehydrogenase 10, 
a member of the short-chain dehydrogenase/reducatse (SDR) family (92). 
MRPP2 has ~260 amino acids (27kDa) and is encoded by HSD17B10 gene on 
chromosome X. MRPP2 has a N-terminal mitochondrial targeting signal and has 
also been identified as HADH2, a hydroxyacyl-CoA dehydrogenase, because it 
catalyzes the β-oxidation of short chain fatty acids and steroids in the presence 
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of a NAD+ cofactor in vitro (93). Numerous neurological diseases have been 
linked to the MRPP2 protein. For example, mutations in the HSD17B10 gene 
cause accumulation of 2-methyl-3-hydroxy-butyryl CoA, a metabolite in 
isoleucine metabolism, that leads to neurological abnormalities in patients (94). 
Moreover, MRPP2 was first discovered as an amyloid β-peptide-binding protein 
in patients with Alzheimer’s Disease (95,96). The amyloid β-peptide has high 
affinity for MRPP2/HADH2 and inhibits the HADH2 activity of MRPP2 at 
micromolar concentrations (97). However, the dehydrogenase activity is not 
essential for RNase P activity since NAD+ is not a required cofactor for pre-tRNA 
cleavage (19). 
    The SDR family of enzymes contain only 15 to 30% sequence similarity, 
including the conserved amino acids in the nucleotide cofactor binding motif and 
the active site (98). However, the SDR family has a conserved α/β sandwich 
structure and these enzymes normally form a functional tetramer complex. The 
α/β sandwich fold of the SDR family is composed of a central β-sheet flanked by 
several α helices (Figure 1-7), which is known as Rossmann-fold motif and is 
proposed to be a RNA-binding domain, as also proposed for MRPP1 (99). 
MRPP2 copurified with the MRPP1 subunit upon 6x His-tag affinity purification 
forming a MRPP1/MRPP2 complex (19). However, the role of MRPP2 in the 
mtRNase P catalysis is still unclear, although it has been proposed that MRPP2 
could be important for (mt)pre-tRNA substrate recognition.  
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Figure 1-7: Crystal structure of human tetrameric HADH2/MRPP2 (PDB code: 
pdb2o23). The β-strands are coloured in red, the α-helices and the loop region in 
blue. The HADH2/MRPP2 is shown in complex with the NAD+ cofactor, shown in 
sphere (100). 
 
Unknown protein, MRPP3 
 
In contrast to MRPP1 and MRPP2, MRPP3 was unannotated in the human 
genome with no known function before identification of human mtRNase P.  
Mass spectrometric analysis of partially purified mtRNase P identified MRPP3 as 
one of the 17 proteins (19). The role of MRPP3 in mtRNase P was confirmed 
when a mitochondrial fraction containing MRPP3 added to the MRPP1/MRPP2 
complex catalyzed cleavage of (mt)pre-tRNA (19). MRPP3 is a protein containing 
583 amino acids that is encoded by the KIAA0391 gene on chromosome 14. 
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Single nucleotide polymorphisms (SNPs) identified in the KIAA0391 gene have 
been linked to coronary artery diseases (76). How these sequence variations in 
the MRPP3 gene contribute to coronary artery diseases is not known but could 
be related to mitochondrial misfunction.  MRPP3 has a N-terminal signal 
sequence that assists the localization of MRPP3 to the mitochondria. Sequence 
alignments of MRPP3 homologs reveal two pentatricopeptide repeat (PPR) 
motifs at the N-terminal end of the protein (19). PPR motifs have been identified 
in proteins in organelles and plants and are involved in post-transcriptional 
events, such as RNA processing, editing and splicing (101-103). PPR domains 
are a ~35 amino acid sequence motif with tandem arrays of 2 to 26 motifs per 
protein (103-106). Structural predictions of the PPR motif suggest the formation 
of two antiparallel α helices. The superhelix of PPR motifs could form a binding 
surface that includes hydrophilic and positively charge residues at the center and 
bottom portion of the groove, respectively (105,107,108). Based on gel mobility 
shift assays, PPR5 and CRP1 (a chloroplast PPR protein), bind preferentially to 
the single stranded RNA than the single stranded DNA or double stranded 
nucleic acids. PPR5 and CRP1 have high affinity for 31-mer RNA and unspliced 
trnG-UCC, a pre-tRNA that associate with a group II intron, respectively. 
Additionally, 9 to 6 nucleotides deletion from the 5’ and 3’ end of the unspliced 
trnG-UCC decreases the affinity for PPR5. Circular dichroism spectroscopy also 
indicates that PPR5 is a monomeric protein that has high α-helix content, which 
is similar to the TPR motifs (104). Together, these data suggested that the PPR 
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motif has a superhelix structure with RNA-binding domains that bind to RNA 
substrate. 
   In addition to the PPR motifs, sequence alignments of MRPP3 homologs reveal 
eight conserved cysteine, aspartate, and histidine residues in the C-terminal 
domain with spacing reminiscent of other metalloproteins. Metal-dependent 
protein nucleases generally include two or more highly conserved acidic active 
site residues that bind metal ions (109,110). Furthermore, the C-terminal of 
MRPP3 has been proposed to have homology to a NYN domain that is the 
catalytic motif of MRPP3.  NYN domains are found in the eukaryotic Nedd4-
binding protein 1 and bacterial YacP nucleases and have four conserved acidic 
residues (111). These conserved acidic residues are predicted to bind metal ions 
and could be part of the protein active site. However, the tertiary structure of the 
NYN domains remains to be elucidated. Furthermore, PFAM analysis of the 
MRPP3 indicates a zinc ribbon domain, suggesting a potential zinc binding site 
and could be involved in RNA binding and/or MRPP3 structural stabilization. 
    Giege and coworkers have isolated three proteins from Arabidopsis thaliana 
that are orthologs to MRPP3, called PRORP1, 2 and 3 (18). However, only 
PRORP1 has been shown to catalyze pre-tRNA cleavage in vitro and is localized 
to the mitochondria and chloroplast. Like MRPP3, PRORP1 has two PPR motifs 
and conserved acidic residues near the C-terminus. Mutation of two conserved 
aspartate side chains to alanine in PRORP1 eliminates the RNase P activity in 
vitro (18) suggesting that these conserved acidic residues are essential for 
RNase P catalysis, perhaps by binding catalytic metal ions. The proposed metal 
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ion binding sites and RNA-binding motifs (PPR motifs) in MRPP3 led to the 
speculation that this enzyme is a novel metal-dependent ribonuclease.  In 
Chapter 4, we investigate the role of metal ions in activating human mtRNase P 
catalysis as well as the function of each of the three proposed mtRNase P 
subunits.  
Objectives of this research 
 
     The overall goal of the research presented in this thesis is to advance our 
understanding of the function of RNase P, including determinants of substrate 
recognition and role of metal ions in catalysis. Chapter 2 will analyze molecular 
recognition of the 5’ leader of pre-tRNAAsp by B. subtilis RNase P. Bioinformatics 
analysis demonstrates sequence preferences in the 5’ leader of the bacterial pre-
tRNAs (49,60).  Biochemical studies in chapter 2 indicate a sequence preference 
in the 5’ leader for pre-tRNA affinity, which is consistent with predictions from the 
bioinformatics analysis. Complementary mutagenesis data indicate that the 
sequence preference at the second nucleotide from the cleavage site (-2 nt) in 
the 5’ leader of the pre-tRNA is due to a trans Watson-Crick-sugar-edge base 
pairing with the G319 in the RNA subunit of RNase P. Furthermore, sequence 
preferences at the third position of the 5’ leader from the cleavage site (-3 nt) 
enhance the metal-stabilized conformational change in RNase P coupled to pre-
tRNA binding.  
     RNase P is a metal-dependent enzyme that catalyzes the 5’ end maturation of 
the pre-tRNA. All known RNase P ribozyme require Mg2+ ions in vivo to stabilize 
the RNA structure and the transition state for pre-tRNA cleavage as well as 
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strengthen the affinity of the RNase P for pre-tRNA. However, the catalytic 
mechanism and catalytic role of metal ions in human mtRNase P, a protein-
based enzyme, is not yet elucidated. Therefore, subsequent chapters describe 
the cloning and purification of human mtRNase P followed by analysis of the 
subunit content and role of metal ions in activating the human mtRNase P 
catalysis.  
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CHAPTER 2 
SUBSTRATE RECOGNITION OF THE 5’ LEADER OF PRE-tRNA BY 
BACTERIAL RNASE P 
Background 
 
    Ribonuclease P (RNase P) is an enzyme that catalyzes the maturation of the 5’ 
end of a precursor-tRNA (pre-tRNA) to form a mature tRNA. This enzyme is a 
ribonucleoprotein composed of a conserved catalytic RNA subunit (P RNA) and a 
minimum of one protein subunit (P protein) (2,3). In Bacteria, the P RNA (~400 
nucleotides) and P protein (~120 amino acids) function synergistically to enhance 
the efficiency of RNase P catalysis under physiological conditions; while the RNA 
is the catalytic subunit, both subunits contribute to substrate recognition. In 
addition to pre-tRNA cleavage, RNase P derived from Escherichia coli (E. coli) 
processes multiple small, stable RNA molecule, including precursor 4.5S RNA 
(pre-4.5S) and mRNA (4,5). RNase P from other sources, such as Bacillus 
subtilis (B. subtilis) show similar promiscuity (8). Although, tertiary structure has 
been proposed as a major feature of RNase P substrate recognition, biochemical 
data suggest that sequence-specific recognition may be important as well. 
However, the molecular details of many of these interactions remain to be 
elucidated. Characterization of the recognition and cleavage mechanisms 
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employed by RNase P will provide valuable insight into how this enzyme 
catalyzes processing of multiple RNA and pre-tRNA substrates in vivo.       
   Biochemical studies indicate that RNase P substrate recognition include a 
number of tRNA tertiary structural features, and specific contacts with the 5’ 
leader, acceptor stem, T stem-loop and the RCCA motif at the 3’ end of the pre-
tRNA (9-12). The 2’-OH to 2’-H substitution studies indicate that P RNA make 
important backbone contact with at least four 2’-OH groups in the T stem-loop of 
pre-tRNA (12,13). Additionally, G292 and G293 (G258 and G259 in B. subtilis) of 
the E. coli P RNA form Watson-Crick base pairs with the 3’ RCCA at the 3 ‘end of 
the pre-tRNA (10,11). The protein component of RNase P also enhances pre-
tRNA affinity by interacting with the 5’ leader (1,14-16). However, RNase P still 
binds and efficiently catalyzes cleavage of pre-tRNAs lacking some of these 
consensus sequences (17). These non-consensus sequences decrease the 
binding affinity of RNase P for mature tRNA. Surprisingly, the binding affinities of 
RNase P for the corresponding pre-tRNA are similar. Therefore, the 5’ leaders of 
these pre-tRNAs have higher affinity interaction with RNase P protein, leading to 
uniform binding and catalysis of all pre-tRNAs by RNase P (14,17). The Harris 
group has demonstrated that the affinity of the leader and the tRNA modules are 
additive and combine to determine the overall substrate affinity. However, the 
details of the protein-leader recognition remain unclear. Bioinformatics analysis 
of pre-tRNA genes from 161 bacterial species reveal that more than 95% of the 
species show a sequence preference at one or more positions within the 5’ 
leader (18). Furthermore, the percentage of bacterial species with a sequence 
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preference in the 5’ leader increases near the pre-tRNA cleavage site. Together, 
the thermodynamic, kinetic and bioinformatics studies indicate that the 5’ leader 
provides a significant contribution to the binding of pre-tRNA by RNase P, 
perhaps in a sequence-specific fashion. 
 The kinetics of pre-tRNA binding to RNase P has been analyzed by stopped flow 
fluorescence spectroscopy, demonstrating a two-step pre-tRNA binding 
mechanism that includes the initial formation of an ES complex (K1), followed by 
a metal-stabilized conformational change (K2) to form the ESM2+ moiety, as 
shown in Scheme 1 (19): 
 (Scheme 1) 
The observed pre-tRNA dissociation constant, Kd,obs, reflects both the binding 
and conformational steps. The observed binding affinity of RNase P for pre-tRNA 
increases as the 5’ leader length increases from 0 to 5 nucleotides. The first step 
in binding, reflected in the equilibrium constant K1 (Scheme 1), is independent of 
the 5’ leader length. However, the equilibrium constant for the conformational 
change step, K2, increases significantly (28-fold) as the 5’ leader length 
increases from 2 to 5 nucleotides (14,19,20).  These measurements suggest that 
the protein-leader interaction forms during the second step, consistent with the 
enhanced FRET signal observed in this step between fluorophores located on 
the 5’ end of pre-tRNA and P protein (20,21). Furthermore, addition of Ca2+ ions 
or Mg2+ ions to the E.S complex, preformed in cobalt hexammine (Co(NH3)63+), 
substantially increases the overall binding affinity of pre-tRNA through formation 
of the ESM2+ complex. Therefore, the conformational change is stabilized both by 
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the interaction between the 5’ leader and the P protein and by binding divalent 
cations (Mg2+ and Ca2+) and this, in turn, enhances the observed pre-tRNA 
affinity.  
    A variety of data, including crystallography, NMR spectroscopy, trFRET and 
crosslinking demonstrates that the 5’ leader of the pre-tRNA interacts with the 
central β-cleft of the P protein and is positioned near the J5/15 and J18/2 helices 
of P RNA in the RNase P-substrate complex (6,7,22-24). Nucleotides at the first, 
second, third and fourth positions in the 5’ leader from the pre-tRNA cleavage 
site are named N(-1), N(-2), N(-3) and N(-4). B. subtilis and E. coli RNase P 
show a strong sequence preference for binding pre-tRNA containing uracil and 
adenosine at N(-1) and N(-4) positions, respectively, consistent with the 
predictions of the bioinformatics analysis (1,18). The U(-1) is the most conserved 
nucleotide within the 5’ leader and is proposed to form a canonical Watson-crick 
with the A248 (A246 in B. subtilis)  at J5/15 of the E. coli P RNA (18). This U(-1) 
and A248 base pair contact is also observed in the crystal structure of T. 
maritima RNase P-substrate complex (6). The A(-4) substrate at the 5’ leader of 
the B. subtilis pre-tRNAAsp forms a hydrogen bond and base stack with the Tyr34 
and Phe20 at the central β-cleft of the P protein (1,6). Interactions between 
RNase P and uracil and adenosine at the N(-1) and N(-4) positions of pre-tRNA 
play a crucial role in increasing binding affinity and maintaining cleavage fidelity 
of the RNase P catalysis. Therefore, the sequence-specific interaction between 
the 5’ leader and the RNase P is important for substrate recognition and catalysis.  
Bioinformatics analyses of the 5’ leader sequences from 161 bacterial pre-tRNA 
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genes also illustrate a significant sequence preferences at N(-2) and N(-3) 
positions (1,18). However, the significance of these sequences preferences for 
RNase P function has not yet been examined. Here, we demonstrate that the 
sequence positions of pre-tRNA modulate pre-tRNA recognition by B. subtilis 
RNase P; mutagenesis and binding affinity measurements indicate a sequence 
preference for adenosine and pyrimidine at the N(-2) and N(-3) positions, 
respectively. Compensatory mutations suggest that the A(-2) nucleotide forms a 
direct contact with the G319 nucleotide at the J18/2 helix of the PRNA and this 
contact is formed in the initial encounter complex (ES). In contrast, the nucleotide 
preference at N(-3) affects the stability of the metal-dependent conformational 
change. Furthermore mutations in the highly conserved RNR motif of the P 
protein (N61, R62, and R65) that contact the P RNA affects the binding affinities 
and sequence selectivity at N(-3) (1,18,25). In summary, these data demonstrate 
that sequence-specific contacts with the N(-2) and N(-3) nucleotides in pre-tRNA 
modulate substrate selectivity in vitro, consistent with the bioinformatics analyses 
of in vivo substrates. 
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Materials and Methods 
RNA and protein preparation 
    B. subtilis P RNA and B. subtilis pre-tRNAAsp substrates with a 5-nucleotide 
leader were prepared by in vitro transcription from linearized DNA templates 
using T7 RNA polymerase as described previously (50). A318 and G319 P RNA 
mutants were prepared using QuikChange site-directed mutagenesis kit 
(Stratagene). B. subtilis pre-tRNAAsp was 5’-end-labeled using [γ-32P]ATP (MP 
Biomedical) and T4 polynucleotide kinase (New England Biolabs). P RNA and 
pre-tRNA were purified by 6% and 12% denaturing polyacrylamide gel 
electrophoresis (PAGE), respectively, followed by washing with TE buffer (10 mM 
Tris-HCl, pH 8.0 and 1 mM EDTA) (15). The 5’-end-labeled substrate was gel-
purified, eluted and extracted with an equal volume of chloroform/phenol followed 
by ethanol precipitation. 
    P protein was expressed in BL21(DE3)pLysS E. coli by growth at 37oC to an 
OD600 of 0.6 to 0.8 followed by induction by 1 mM isopropylthio-β-D-
galactopyranoside.  P protein was purified from the soluble fraction of the cell 
lysate by CM-Sepharose ion-exchange chromatography in the presence of urea 
(26). Variants of the B. subtilis protein with site-specific cysteine and alanine 
mutations were prepared as described previously (26). Before use, P protein was 
dialyzed overnight at 4oC in the proper reaction buffer, and final concentrations 
were determined by absorbance at 280 nm (ε280 = 5120 M-1 cm-1) (26). 
    Before use, P RNA and pre-tRNA were heat denatured at 95oC for 3 min in 
water, then incubated at 37oC for 10 min. To fold the RNAs, 50 mM Tris/MES, 
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and an appropriate final concentration of monovalent and divalent metal ions 
were added to the RNAs and incubated at 37oC for 30 min. After renaturation, P 
RNA was buffer exchanged and reconcentrated in the reaction buffer using an 
Amicon ultracentrifugal filter unit (10,000 MWCO) for three times to ensure the 
correct [Ca2+]f. 
Substrate affinity, Kd,obs measurements 
    Substrate affinities were measured by centrifuge gel filtration using a spin 
column (Spin-X, Corning Incorporated) with Sephadex G-75 resin (Sigma-
Aldrich). The total substrate concentration ([Stot]) was maintained at < 20% of the 
total RNase P concentration ([Etotal]). Buffer conditions used for Kd,obs 
measurements were: 50 mM Tris/MES, ~ 400 mM KCl, pH 6.0, varying (0 to 10 
mM CaCl2) concentrations of [Ca2+]f with ionic strength maintained at 410 mM by 
varying the KCl concentration (~400 mM KCl). RNase P holoenzyme (1.2 nM to 
2.7 µM) was reconstituted by adding a 1:1 ratio of dialyzed P protein and folded 
P RNA and incubating at 37oC for 30 min. These concentrations are significantly 
higher than the P RNA-P protein affinity under all conditions (27,28). Pre-tRNA 
substrates were renatured as described above. RNase P and pre-tRNA were 
mixed and incubated at 37oC for 5 min prior to loading onto preequilibrated gel 
filtration spin columns. Columns were centrifuged at 6000 rpm for 15 sec, and the 
radioactivity in the filtrate (bound substrates) and retentate (unbound substrates) 
was measured by Cerenkov scintillation counting. Dissociation constants, Kd,obs 
were determined by fitting a single binding isotherm to the dependence of the 
fraction bound on the RNase P concentration (Eq.1).  
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Equation 1       
[ES]
[Stotal ]
=
1
1+ Kd,obs[Etotal ]
 
K1 and K1/2Ca measurements 
The Ca2+-dependence of the affinity of RNase P for pre-tRNA was measured as 
described above except that the folding and binding buffer contained: 50 mM 
Tris-MES, 380 mM KCl, 2 mM Co(NH3)6Cl3 (pH 6.0) and varying free CaCl2 
concentration (0 to 10 mM). The Kd,obs for pre-tRNA was measured at various 
concentration of [Ca2+]f using the centrifuge gel filtration columns. Equation 2 was 
fitted to the dependence of Kd,,obs on the [Ca2+]f to determine the values of K1 
(Scheme 1) and K1/2Ca. 
Equation 2      Kd,obs =
K1(1+ [Ca
2+ ]n
K2n
)
1+ [Ca
2+ ]n
(K1/2Ca )n
 
Single turnover kinetic measurements 
    Single turnover experiments were performed in 50 mM MES/Tris, 191 mM KCl, 
and 5 mM CaCl2 buffer (pH 8.0) at 37oC using excess RNase P holoenzyme 
concentrations ([E]/[S] >> 5; [E] 0.6 nM to 2 µM; [S] ≤ 0.1 nM) with limiting 
radiolabelled pre-tRNAAsp. The 5’ leader product was separated from the pre-
tRNAAsp substrate on a 20% PAGE and quantified using a PhosphorImager 
(Amersham Bioscience Corp.). The observed rate constants, kobs were 
determined by fitting a single-exponential equation to the data (Eq. 3).                    
Equation 3    [P]= [P]!(1" e"kobst )  
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Results 
 
N(-2) and N(-3) sequences in the 5’ leader of pre-tRNA contribute to the 
RNase P binding affinity. 
    Previous studies have shown that the 5’ leader of pre-tRNA enhances the 
binding affinity and cleavage rate constants catalyzed by RNase P (1,7,9,14,15). 
Bioinformatics analyses of the sequences of the 5’ leader of B. subtilis pre-tRNA 
indicate a sequence preference for adenosine at N(-2) position of the pre-tRNA 
(Figure 2-1). However, the sequence preference at the N(-3) position is not as 
strong as the N(-2) position in the B. subtilis 5’ leader of the pre-tRNA. Bacterial 
species from Chlamydophila, Clostridium and Streptomyces indicate a high uracil 
and cytosine sequence preference at N(-3) position of the 5’ leader of pre-tRNA 
(unpublished data). The sequence preferences observed by bioinformatics might 
reflect in vivo substrate recognition preferences for cleavage catalyzed by RNase 
P (1,18). To test this hypothesis and to evaluate the importance of N(-2) and N(-3) 
sequences for molecular recognition by RNase P, we measured the affinity of the 
B. subtilis RNase P for pre-tRNAAsp with varying sequences at the N(-2) and N(-3) 
positions using centrifuge size-exclusion chromatography. In these binding 
experiments, the metal cofactor, Mg2+, is replaced by Ca2+, which stabilizes the 
formation RNase P-pre-tRNA complex by RNase P, but cleavage is slow (t1/2 ≈ 5 
hours) (29). These experiments were carried out in low mM (≤ 5 mM) 
concentrations of divalent cations to mimick in vivo conditions.  
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Figure 2-1: Genomic analysis of the conservation of the 5’ leader sequence of 
B.subtilis pre-tRNAs by using sequence-Logos adapted from Koutmou K.S. et. al., 
2010 (1). 
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The affinity measurements demonstrate a sequence preference at N(-2) for 
RNase P binding pre-tRNA; the substrate with A(-2) binds ~ 2-fold more tightly 
than C(-2) and U(-2) and ~ 10-fold more tightly than G(-2) (Figure 2-2A and Table 
2-1). The preference for A and discrimination against G at N(-2) is consistent with 
the bio-informatics analysis. Similarly, the sequence at N(-3) also affects binding 
affinity where U(-3)- and C(-3)-pre-tRNAAsp bind ~6.5 fold more tightly than 
substrates with an A or G at this position, suggesting that B. subtilis RNase P 
prefers a pyrimidine at N(-3). This is a larger discrimination than suggested by 
the bioinformatics.  These data demonstrate that the sequences at N(-2) and N(-
3) affects the affinity of RNase P for pre-tRNA. 
   To evaluate whether, the leader sequence of pre-tRNA affects RNase P 
catalysis, the single turnover cleavage rate constants were measured at 
saturating RNase P. The sequence at N(-2) has affects this rate constant < 2-fold 
with a maximal kobs of 0.09 ± 0.01 min-1 for A(-2)-pre-tRNA and a minimum kobs of 
0.05 ± 0.01 min-1 for C(-2)-pre-tRNA (Table 2-1). Thus, the leader sequence 
preference affect the stability but not the reactivity of the ES complex, consistent 
with the direct interaction of the leader with the non-catalytic protein subunit.  
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Table 2-1. Sequence of N(-2) and N(-3) nucleotides in the 5’ leader of pre-
tRNAAsp affect recognition by RNase P 
                   Kd, obs (nM)         kobs (min-1) 
Substrate N(-2)a N(-3)b  N(-2)c 
Adenosine 4 ± 1 26 ± 6  0.09 ± 0.01 
Cytosine 9 ± 1 4 ± 1  0.05 ± 0.01 
Guanosine 39 ± 6 23 ± 4  0.086 ± 0.002 
Uracil 10 ± 2 4 ± 0.6  0.071 ± 0.004 
a Dissociation constants, Kd,obs measurements of pre-tRNAAsp with a 5 nucleotide 
leader of the sequence containing 5’ GAANU with varying sequence at N(-2). 
Conditions: 50 mM MES/Tris (pH 6.0) at 37oC, 5 mM CaCl2, and [KCl] was 
adjusted to maintain ionic strength at 410 mM  KCl. 
b Dissociation constants, Kd,obs measurements of pre-tRNAAsp with a 5 nucleotide 
leader of the sequence containing 5’ GANAU with varying sequence at N(-3). 
Conditions: Same as (a) except with 3 mM CaCl2. 
c Single turnover rate constant measured at saturating enzyme concentration for 
cleavage of N(-2)-pre-tRNAAsp. Conditions: 50 mM MES/Tris (pH 8.0) at 37oC, 
191 mM KCl and 5 mM CaCl2. 
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Figure 2-2: Sequence preference of N(-2) and N(-3) positions at 5’ leader of the 
pre-tRNAAsp. (A) Dissociation constants, Kd,obs measurements of RNase P with 
pre-tRNAAsp with adenosine, cytosine, uracil and guanosine at N(-2) position of 
the 5’ leader in 50 mM Tris/MES, 395.5 mM KCl, 5 mM CaCl2, pH 6.0. (B) 
Dissociation constants, Kd,obs measurement of RNase P with pre-tRNAAsp 
containing adenosine, cytosine, uracil and guanosine at N(-3) position of the 
5‘ leader in 50 mM Tris/MES, 401.5 mM KCl, 3 mM CaCl2 at pH 6.0. Dissociation 
constants (Kd,obs) are calculated from a fit of a binding isotherm to these data.  
 
A 
B 
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Compensatory mutations suggest base pairing between N(-2) of pre-tRNA 
leader and G319. 
    Crosslinking and affinity cleavage assays indicate that the N(-2) and N(-3) 
nucleotides in the RNase P-pre-tRNA complex in solution are located near the 
J5/15 and J18/2 helices in B. subtilis P RNA, while N(-3) through N(-7) are  
positioned near the central β-cleft of the P protein (Figure 2-3A) (7,16,22). In 
addition, current crystal structure of the T. maritima RNase P.5’ leader complex 
suggests that the N(-2) and N(-3) nucleotides form contacts with the G295 and 
U294, respectively, (corresponding to G319 and A318 in B. subtilis P RNA) at the 
J18/2 helix of the P RNA (Figure 2-5) (6,30). To test the functional significance of 
contacts between these nucleotides in P RNA and the N(-2) and N(-3) 
nucleotides in pre-tRNA, we employed a compensatory mutation approach.  
   Wild type RNase P preferentially binds to pre-tRNA containing A(-2) in the 
leader (Figure 2-1). The A nucleotide at N(-2) cannot form a Watson-crick base 
pair with either G319 or A318 in P RNA. However, the NMR and crystal 
structures of RNA demonstrate the formation of a variety on non-Watson-Crick 
base pairing (31,32). To test for the formation of one of these alternative 
structure we measured the affinity of RNase P with mutations at A318 and G319 
with pre-tRNA containing variable sequence at N(-2) and N(-3) (Table 2-2). 
Mutation of A318 to G, C, or U decreases the binding affinity for A(-2)-pre-tRNA 
by 4- to 20-fold, (Table 2-2) suggesting a possible base pairing interaction. To 
test this proposal, we assessed the effect of compensatory mutations at A318 
and N(-2)-pre-tRNA on binding affinity. All of the nucleotide substitutions at 318 
 45 
decrease the binding affinity of pre-tRNA by 2- to 75-fold, regardless of the 
nucleotide at N(-2) in pre-tRNA. Therefore no compensatory rescue is observed, 
suggesting that A318 does not base pair with the N(-2) nucleotide in pre-tRNAAsp. 
   Nucleotide substitution at G319 lead to more modest changes in affinity with 
both enhanced (< 3-fold) and diminished (< 10-fold) affinity (Table 2-3). 
Furthermore, compensatory substitutions are observed. The binding affinity of 
A319 RNase P for G(-2)-pre-tRNAAsp (Kd,obs of 5 ± 1 nM) is comparable to the 
affinity of wild type (G319) RNase P for A(-2)-pre-tRNAAsp (Kd,obs of 4 ± 0.7 nM), 
suggesting that the A319/G(-2) and G319/A(-2) are equivalent. Likewise, the 
following pairs have similar binding affinities: (a) C319/U(-2) and U319/C(-2) 
(Kd,obs of 5 ± 0.8 nM and 4.8 ± 1 nM); (b) C319/G(-2) and G319/C(-2) (Kd,obs of 12 
± 1 nM and 9 ± 1 nM); and (c) U319/G(-2) and G319/U(-2) (Kd,obs of 7 ± 1 nM and 
10 ± 2 nM). These compensatory mutations suggest that the N(-2) nucleotide 
forms direct contact with G319. In contrast, single turnover measurements of the 
G319A, G319C and G319U RNase P mutants at saturating enzyme 
concentration demonstrate that the kobs of ≤ 2-fold relative to that of wild type 
RNase P (Figure 2-3B). These results indicate that mutation at G319 has little 
effect on the RNase P cleavage. In summary, these data suggest that the N(-2) 
nucleotide forms a direct contact with G319, and not A318, in the J18/2 helix of 
the P RNA, consistent with the crystal structure of the T. maritima RNase 
P.tRNA.5’leader complex (6).  
   To examine possible base pairing between A318 and N(-3) nucleotide as 
visualized in the crystal structure, we measured the binding affinity of RNase P 
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mutants at A318 with the N(-3) substrates. Mutations at the A318 nucleotide 
decrease the binding affinity of the RNase P for C(-3) substrate, by 3- to 100-fold, 
suggesting a possible interaction.  The binding affinities of A318G for A(-3), C(-3) 
and G(-3)-pre-tRNAAsp are similar (Kd,obs ~ 300 nM). While the U(-3)-pre-tRNAAsp 
has a higher affinity (Kd,obs ~100 nM). However, substitution of the C(-3) substrate 
with various nucleotides at N(-3) pre-tRNA does not rescue the binding affinity of 
the A318C and A318U mutants (Table 2-2). The affinity of A318C RNase P with 
A(-3) pre-tRNA (C/A pair) is 50-fold weaker than the affinity of wild type RNase P 
with C(-3) pre-tRNA (A/C pair). Similarly the affinity of A318U RNase P for A(-3)-
pre-tRNA (U/A pair) is 10-times weaker than wild type RNase P with U(-3)-pre-
tRNA (A/U pair). Additionally, binding affinity of the mature tRNA for A318C, 
A318U and A318G RNase P mutants are > 5-fold (Kd,obs > 500 nM) relative to the 
wild type RNase P (Kd,obs ~ 200 nM), suggesting that mutation at A318 nucleotide 
perturb the local structure stability of P RNA. Therefore, no compensatory 
mutations are observable in the binding data between A318 and, N(-3) nucleotide 
in pre-tRNA, providing no evidence for base pairing.  
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Table 2-2. Binding affinity, Kd,obs of the N(-2), N(-3) and mature tRNA substrates 
for A318 mutants 
                              Dissociation Constant, Kd,obs (nM) 
Substrate WT A318 A318C A318G A318U 
A(-2) 4 ±0.7 23 ± 6 84 ± 18 18 ± 5 
C(-2) 9 ± 1 139 ± 23 130 ± 21 21 ± 4 
G(-2) 39 ± 6 183 ± 25 318 ± 53 40 ± 8 
U(-2) 10 ± 2 95 ± 28 246 ± 50 38 ± 6 
     A(-3) 26 ± 6 204 ± 31 349 ± 80 41 ± 7 
C(-3) 4 ± 0.8 10 ± 3 307 ± 64 8 ± 2 
G(-3) 25 ± 4  66 ± 11 337 ± 160 18 ± 6 
U(-3) 4 ± 0.6 45 ± 14 107 ± 26 16 ± 3 
     tRNA 230 ± 112 > 500 > 500 > 500 
 a Dissociation constants, Kd,obs measurements of N(-2) pre-tRNAAsp for different 
nucleotide at A318 of the P RNA in 50 mM MES/Tris (pH 6.0) at 37oC, 5 mM 
CaCl2, and [KCl] was adjusted to maintain ionic strength. The leader sequence is: 
5’ GAANU 
b Same as (a) except with N(-3) substrates and 3 mM CaCl2. The leader 
sequence is: 5’ GANAU. 
b Same as (a) except with mature tRNA substrate.  
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Table 2-3.  Binding affinity, Kd,obs of the G319a mutants for N(-2) substrates. 
 
a Dissociation constants, Kd,obs (nM) measurement of N(-2) pre-tRNA for different 
nucleotide at 319 position of the P RNA in 50 mM MES/Tris (pH 6.0) at 37oC, 5 
mM CaCl2, and [KCl] was adjusted to maintain ionic strength. The leader 
sequence is: 5’ GAANU. 
b The G at position 319 is the wild type sequence of B. subtilis P RNA. 
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Figure 2-3: (A) Single turnover measurement of the RNase P catalyzed 
hydrolysis of N(-2) substrates. 32P-labeled pre-tRNAAsp (~0.01 nM) was incubated 
with saturating enzyme concentration (40 – 360 nM) in 50 mM MES/Tris, pH 8.0, 
191 mM KCl and 5 mM CaCl2 at 37oC. (B) Single turnover reaction of the A(-2) 
substrate by various nucleotide at G319 of the PRNA. 32P-labeled pre-tRNAAsp 
(~0.01 nM) was incubated with saturating enzyme concentration (0.25 – 1 µM) in 
50 mM MES/Tris, pH 8.0, 191 mM KCl and 5 mM CaCl2 at 37oC. The reaction 
was quenched by addition of 50 mM EDTA and the products were separated by 
PAGE and analyzed using a phosphoimager. The fraction of pre-tRNA cleaved 
by the RNase P as a function of time was plotted and fitted using Eq. 3 to obtain 
the observed rate constants, kobs. 
A 
B 
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Mutations in P protein affect Sequence preference at N(-3) pre-tRNA. 
 
Structural and biochemical data suggest that the N(-3) nucleotide of pre-tRNA is 
located near the P protein-P RNA interface and may therefore be sensitive to 
alterations in either subunit. Mutations in the central cleft and highly conserved 
RNR motif of the P protein have previously been shown to alter the N(-4)-pre-
tRNA affinity and selectivity (1). Therefore, we tested whether these mutations 
also affect selectivity at the N(-3) position. As shown in Table 2-4, mutations in 
RNase P protein decrease pre-tRNA binding affinity substantially (2- to 30-fold). 
The F16A mutation, located in the first strand of the central β sheet, where the 
leader binds (16,33), and the K64C and R68A mutations in the RNR motif do not 
significantly affect the binding selectivity. The selectivity ratio (KD, A(-3)/KD, C(-3)) in 
the F16A, K64C and R68A mutation is comparable to that of wild type RNase P. 
In contrast, the N(-3) selectivity virtually disappears (KD, A(-3)/KD, C(-3) ~ 1.4) in the 
R62 mutation located in the RNR motif. Furthermore, selectivity decreases in the 
R65A and N61C mutations in the RNR motif by ≤ 2-fold. The R65A and N61A 
also affect the N(-4) sequence selectivity by ≤ 2-fold. Based on the crystal 
structure of T. maritima RNase P.tRNA.5’ leader complex and our current model 
of B. subtilis RNase P.pre-tRNA complex, the R62 is ≥ 10 Å away from the N(-3) 
nucleotide. Therefore, the R62A, R65A and N61C mutations in the RNR motif 
indirectly affect the N(-3) sequence selectivity. 
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Table 2-4. Binding affinities of the P protein mutants for N(-3) substrates. 
               Kd,obs (nM)a            Kd,mutants/Kd,native 
Protein A(-3) C(-3) A(-3)/C(-3) 
Native 26 ± 6 4 ± 1 6.5 ± 2.2 
F16A 147 ± 34 27 ± 5 5.4 ± 1.6 
R65A 102 ± 20 34 ± 6 3.0 ± 0.8 
R68A 61 ± 15     13 ± 3 4.7 ± 1.6 
N61C 380 ± 81 109 ± 68 3.5 ± 2.3 
R62C 171 ± 40 120 ± 61 1.4 ± 0.8 
K64C 168 ± 47 22 ± 3 7.6 ± 2.4 
a Dissociation constants, Kd,obs of the P protein mutants for A(-3) and C(-3) 
substrates were measured at 50mM MES/Tris (pH 6.0) at 37oC, 3 mM CaCl2, and 
[KCl] was adjusted to maintain ionic strength. 
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Interaction of RNase P with N(-2) and N(-3) pre-tRNA differentially stabilize 
the encounter complex and the metal-dependent conformational change. 
   Pre-tRNA binds to RNase P in a two-step mechanism: the formation of an E.S 
encounter complex followed by a metal-stabilized conformational change in 
which the pre-tRNA leader contacts the P protein (scheme 1) (19). Therefore pre-
tRNA affinity depends on the concentration of divalent cations. Additionally, the 
binding selectivity for the nucleotide at N(-4) in the pre-tRNAAsp varies with Ca2+ 
concentration. Therefore, to further investigate recognition of the N(-2) and N(-3) 
nucleotides in the pre-tRNA leader we measured the calcium-dependence of 
binding affinity for A(-2)-, G(-2)-, A(-3)-, and C(-3)-pre-tRNA in Co(NH3)63+. Cobalt 
hexammine is an outer sphere metal ion that mimics Mg(OH2)62+ by stabilizing 
folded RNase P and pre-tRNA. Under these conditions the observed binding 
affinity of RNase P for each of the pre-tRNA substrate has a hyperbolic 
dependence on the Ca2+ concentration with a K1/2Ca varying from 19 to 420 µM.  
    The pre-tRNA binding affinity in cobalt hexamine approximates the equilibrium 
constant for the formation of the initial encounter complex (K1, Scheme 2) (19,34-
36). Substitution of G for A at N(-2) in pre-tRNA decreases the value of K1 from 
90 ± 21 nM to 236 ± 60 nM, indicating formation of an interaction with this 
nucleotide in the encounter complex (Figure 2-4A). In contrast, the binding 
affinity of RNase P for A(-3) and C(-3) pre-tRNA in cobalt hexammine are 
comparable (90 ± 20 nM and 154 ± 27 nM), suggesting little contact in the initial 
encounter complex (Figure 2-4B). The calcium dependence of the binding affinity 
(K1/2Ca) reflects a combination of calcium affinity and the equilibrium constant for 
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the conformational changes. The value of K1/2Ca is unaffected by the identity of 
the nucleotide at N(-2) indicating little influence on the metal-dependent 
conformational change (Figure 2-4A). However, the K1/2Ca for A(-3) pre-tRNA is 
20-fold higher (420 ± 30 µM) compared to that of the C(-3) pre-tRNA (19 ± 3 µM) 
suggesting that the interaction with this nucleotide occurs at the conformational 
change step (Figure 2-4B). The equation 2 is fitted to the dependence of Kd,obs on 
calcium concentration and has a n ~ 1 for A(-2), G(-2), C(-3) and A(-3) pre-tRNAs. 
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Scheme 2. (A) Metal dependence of pre-tRNA binding mechanism by the RNase 
P. (B) The expanded minimal metal-stabilized conformational change 
mechanism. (C) Equilibrium constant expressions to define the parameters in (A) 
and (B). 
 
(A) 
E + S + nCa2+ K1! "# ES + nCa2+
K2 ! !K1/2Ca
ECan2+ + S K3! "# ES
$Can2+
 
  
 
(B)  
 
ES + nCa2+ K4! "# ESCan2+ K5! "# ES$Can2+  
 
(C)  
   
Kd,obs =
K1(1+ [Ca
2+ ]n
K2n
)
1+ [Ca
2+ ]n
(K1/2Ca )n
K1 = [E][S] / [ES]
K2 = [E][Ca2+ ]n / [ECan2+ ]
K3 = [ECan2+ ][S] / [ES!Can2+ ]
K4 = [ES][Ca2+ ]n / [ESCan2+ ]
K5 = [ESCan2+ ] / [ES!Can2+ ]
K1/2Ca = [ES][Ca2+ ]n / [ES!Can2+ ]= K4K5
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Figure 2-4. Metal dependence of pre-tRNAAsp binding affinity by RNase P. (A) 
Metal dependent measurements of A(-2) () and G(-2) () substrates binding 
affinity by RNase P. 0 to 10 mM of CaCl2 was titrated into the 2 mM Co(NH3)63+ 
to obtain the Kd,obs of the RNase P for N(-2) substrates at various [CaCl2] (see 
materials and methods). Kd,obs values as a function of [CaCl2] was plotted and 
fitted using Eq. 2 to obtain the initial formation of ES complex, K1 and the metal 
stabilized conformation change step, K1/2Ca. The K1 and K1/2Ca for A(-2) and G(-2) 
substrates are  K1: 90 ± 21 nM and 235 ± 60 nM, K1/2Ca : 416 ± 27 µM and 387 ± 
73 µM, respectively. (B) The K1 and K1/2Ca for A(-3) () and C(-3) () substrates 
are  K1: 90 ± 20 nM and 154 ± 27 nM, K1/2Ca: 416 ± 27 µM and 19 ± 3 µM, 
correspondingly. 
B 
A 
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Discussion 
 
Specific contact between G319 in P RNA and N(-2) in pre-tRNA 
    Recent bioinformatics and biochemical studies have demonstrated sequence-
specific contact between the N(-1) and N(-4) positions of the 5’ leader and the 3’ 
RCCA motif of pre-tRNA for B. subtilis and E. coli RNase P (1,18). Bioinformatics 
data suggest a sequence preference for RNase P at the N(-2) position of  the 5’ 
leader of the B. subtilis pre-tRNAAsp. Here we have confirmed the bioinformatics 
prediction, demonstrating that B. subtilis RNase P preferentially binds A(-2) pre-
tRNA relative to G(-2) pre-tRNA by 1.4 kcal/mole at 5 mM CaCl2 in vitro (Table 2-
1). While substitution of the A(-2) nucleotide with C, U or G decreases the 
binding affinity, the  single turnover rate constant for pre-tRNA cleavage 
catalyzed by RNase P is unchanged. These data indicate that the nucleotide 
substitution alters an interaction with RNase P but does not change the structure 
of the RNase P.pre-tRNA complex.  
 Compensatory mutations implicate a sequence specific interaction between the 
N(-2) position of pre-tRNA and the G319 nucleotide at the J18/2 helix of the P 
RNA. The binding affinity of wild type RNase P for pre-tRNA is disrupted by 1.4 
kcal/mole when the A nucleotide at the -2 position is replaced by G. However, 
high affinity binding between the RNase P and pre-tRNA is recovered when the 
G(-2) substrate binds to the G319A RNase P mutant, suggesting a compensatory 
base-pairing interaction between G319/A(-2) and A319/G(-2). In the same 
manner, a compensatory base-pairing substitution is observed for the following 
pairs: C319/A(-2) and A319/C(-2); C319/G(-2) and C319/G(-2); C319/U(-2) and 
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U319/C(-2); and G319/U(-2) with U319/G(-2). These results strongly suggest a 
direct contact between G319 of P RNA and N(-2) of pre-tRNA. 
    Interestingly, the affinity of most of these base-pairing substitutions are within 
2 to 3-fold of each other, with the exception of G319/G(-2) base pair decreases 
binding affinity 10 to 40-fold different in Kd,obs relative to the G319/A(-2) and 
A319/A(-2) base pairs respectively (Table 2-3). It is possible that this interaction 
was selected to minimize the sequence-specific interaction to enhance cleavage 
of a wide variety of substrates. To further examine this phenomenon, genomic 
sequences at the 319 position of P RNA and the N(-2) position of the 5’ leader 
from 40 bacterial RNase P and pre-tRNA species were compiled and aligned to 
ascertain whether the P RNA sequence at position 319 co-varies with the 
nucleotide preference at the N(-2) position (Table 2-5). The sequence alignments 
of P RNA from 40 species indicate that the sequence at position 319 is split 
equally between A (21/40) and G (19/40). The majority of RNase P species have 
a modest preference for A(-2) pre-tRNA (28/40) although preference for G and U 
are also observed (Table 2-5). These comparisons indicate that the G-A (14/40) 
and A-A (15/40) pairs at 319/N(-2) are the most frequent combination.  
    Based on the NMR and crystal structures of the RNA, Leontis and coworkers 
have proposed 13 possible non-Watson-Crick RNA base pairing motifs (31,32). 
Each motif is characterized by a unique isosteric matrix indicating pairs of 
nucleotides that can form a similar geometry and glycosidic bond orientations, 
suggesting possible base pair substitutions for each base-pairing motif. A 
comparison between the isotericity matrices and the identification of  
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Figure 2-5: Structure of RNase P with bound pre-tRNA is generated using the 
Pymol program. (A) The crystal structure of T. maritima RNase P.tRNA.5’ leader 
complex with 4.2 Å resolution (6). The N(-1) and N(-3) nucleotides, shown in 
yellow, are proposed to contact the A213 (gray) and U294 (magenta) nucleotides, 
respectively, while the N(-2) nucleotide, indicated in red, is proposed to be in 
contact with G295 (green). (B) The structural model B. subtilis RNase P is based 
on photocrosslinking and affinity cleavage data with 10 Å resolution (7). The N(-2) 
nucleotide, shown in red, is proposed to base pair with the G319 nucleotide 
(green). The N(-1) and N(-3) nucleotides are shown in yellow. The N(-3) 
nucleotide is proposed to base pair with A318 nucleotide (magenta). These 
contacts are not included in this model. 
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compensatory mutations at the G319 and N(-2) nucleotide from the binding 
affinity data, suggests the formation of a trans-Watson-Crick-sugar-edge 
interaction between the G319 and the N(-2) nucleotide (Figure 4-5). Because the 
sequence preference at the N(-2) position varies depending on the species while 
in bacteria is either A or G, we propose that the sugar-edge side of G319 directly 
contacts with the Watson-Crick side of the N(-2) nucleotide (Figure 4-5). This 
type of interaction allows G319 to directly contact various N(-2) nucleotides with 
different Watson-Crick structure, which allows bacterial RNase P to recognizes 
RNA substrates with variable sequence at N(-2) and maintains comparable 
binding affinity for the majority of nucleotide pairs between 319 and N(-2).  
Sequence at N(-3) affect binding affinity 
    Bioinformatics analysis of the 5’ leader of B. subtilis pre-tRNA shows no 
substantial sequence preference at the N(-3) position (1). However, the binding 
affinity data indicate a sequence preference for C(-3)- and U(-3)-pre-tRNA 
relative to the A(-3)- and G(-3)- by 1.2 kcal/mole (5’ GANAU-pre-tRNAAsp). 
Sequence preference for U and C at the N(-3) position is likely due to a 
combination of factors, including the structure of the 5’ leader in unbound pre-
tRNA and interaction with P RNA and/ or P protein and in the metal-stabilized 
conformational change occurs after pre-tRNA binding. From a structural 
perspective, addition of a purine at the N(-3) position in the 5’ GANAU creates 5’-
GAAAU and 5’-GAGAU sequences that enables base stacking of the three 
purine nucleotides. This could decrease the flexibility of the 5’ leader sequences 
in unbound pre-tRNA and increase the energy barrier for contacting the P protein 
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in RNase P. Disruption of this base stacking upon binding to RNase P could 
explain the decreased affinity of pre-tRNA with A or G at N(-2) (Table 2-1). This 
explanation is also consistent with the observed effect of the N(-3) substitutions 
on the decreased stability of the metal-dependent conformational change, where 
the 5’ leader docks into the binding cleft of the P protein (1,7,16). Pyrimidines (C 
and U) at the N(-3) position will decrease base stacking in unbound pre-tRNA 
and thus enhance the overall binding affinity.  
    Wild type RNase P preferentially binds to C(-3) pre-tRNAAsp relative to the A(-3) 
substrate by 1.2 kcal/mole. However, the binding affinity of pre-tRNA and the 
specificity ratio of the A(-3) substrate relative to the C(-3) substrate for RNase P 
is altered by mutations in the RNR motif (N61C, R62C and R65A) up to 0.9 
kcal/mole (Table 2-4). While a mutation in the central cleft of P protein (F16A) 
has little effect on selectivity, these results demonstrate that side chains in the 
RNR motif of the P protein effect recognition of the N(-3) nucleotide of pre-tRNA. 
Whether this is a direct or indirect effect is not clear. Affinity cleavage assays 
suggest that the N(-3) nucleotide is located within 15 Å of the RNR motif and the 
first β-strand of central β-cleft of the P protein (7,16). However, the T. maritima 
crystal structure of the RNase P.tRNA.5’ leader complex positions the -3 
nucleotide 6.5 Å away from the RNR motifs and the first β-strand of central β-cleft 
of the P protein (6).  Furthermore, the R60 and R62 mutations that alter 
recognition of the N(-4) position in pre-tRNA also affect tRNA affinity, suggesting 
an indirect interaction (1,25). Nonetheless, selectivity at the N(-3) position is 
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altered by changes in both P RNA and P protein, suggesting that it is located 
near the P RNA/Pprotein subunit interface.  
     The crystal structure of the T. maritima RNase P.tRNA.5’ leader (leader 
sequence of 5’ GGCGU) positions the N(-3) nucleotide near U294 of P RNA 
(A318 in B. subtilis P RNA) and ≥ 10 Å from the protein subunit. However, 
compensatory mutations at the A318 and N(-3) nucleotides do not rescue the 
RNase P binding affinity, providing no evidence for direct contact between the 
A318 and N(-3) nucleotides. There are numerous explanations for these results. 
Based on the metal-dependent pre-tRNA binding mechanism, recognition of the 
N(-3) nucleotide of pre-tRNA is coupled to the metal stabilized conformational 
change step that occurs after binding to RNase P (Figure 2-4B). Since the crystal 
structure visualizes the RNase P.tRNA.5’ leader product complex, it is possible 
that the position of N(-3) is altered. Alternatively, mutations at A318 in B. subtilis 
P RNA may alter the structure such that compensatory affects are not observed.  
Bioinformatic analysis products RNase P substrate preferences 
     The binding affinity data for RNase P to pre-tRNAs with varying sequence at 
N(-2) correlate well with the preferences observed in the bioinformatics analysis 
(A>, C, U >G). This correlation suggests that molecular recognition between the 
N(-2) nucleotide of pre-tRNA and G319 of P RNA contribute to the observed 
preferences in the genomic sequences. Furthermore, the observed sequence 
preferences in the pre-tRNA leaders likely co-evolve with the binding preferences 
of RNase P. Therefore, the observed species-specific alterations in the genomic 
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sequences of pre-tRNA leaders likely also indicate alterations in RNase P 
substrate selectivity. 
    While the bioinformatics data correlate well with the RNase P substrate 
preferences at N(-1), N(-2) and N(-4) (1), no genomic preferences are observed 
for N(-3) despite clear binding affinity preferences in RNase P. This discrepancy 
could suggest that interactions between RNase P and the N(-3) nucleotide are 
key for tuning the affinity of the leader relative to the tRNA affinity to obtain the 
observed uniform binding of all pre-tRNA substrates that is important for 
maintaining effective concentrations of all processed cellular tRNAs. 
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Table 2-5. Sequence alignments of J5/15 and J18/2 helix of the P RNA and the 
N(-2) nucleotide. 
Bacterial PRNA                           J5/15a   J18/2a    N(-2)b 
Agrobacterium tumefaciens                 CAA   AGA UGA AU   G 
Bacillus anthracis                        AAA   AGA UAG AU   A 
Bacillus subtilis                         AAA   AGA UAG AU   A 
Bacillus Halodurans                       AAA   AGA CAG AU   A 
Bacteroides thetaiotaomicron              UAA   AGA UAA AU   A 
Bordetella pertussis                      CAA   AGA GGA AU   C/U 
Borrelia burgdorferi                      CAA   AGA GAG AU   U 
Caulobacter crecentus                     CAA   AGA GGA AU   G 
Clostridium acetobutylicum                CAA   AGA UAG AU   A   
Chlamydia trachomatis                     CAA   AGA UGA AU   A   
Chlorobium tepidum                        CAA   AGA UAA AU   A 
Deinococcus radiodurans                   CAA   AGA CAG AU   G 
Enterococcus faecalis                     CAA   AGA UAG AU   U 
E. coli                                   CAA   AGA UGA AU   A 
Haemophilus influenza                     CAA   AGA GGA AU   A 
Helicobacter pylori 26695                 CAA   AGA UAA AU   A/U 
Lactobacillus acidophilus                 UAA   AGA UAG AU   A 
Mycobacterium avium                       CAA   AGA UGG AU   A   
Mycobacterium bovis                       CAA   AGA UGG AU   A/G 
Mycobacterium leprae                      CAA   AGA UGG AU   A 
Mycobacterium tuberculosis                CAA   AGA UGG AU   A/G 
Mycoplasma genitalium                     AAA   AGA UAA AU   A 
Mycoplasma hyopneumoniae                  AAA   AGA UAA AU   A 
Mycoplasma pneumoniae                     AAA   ACA UAA AU   A 
Neisseria gonnorhoeae                     CAA   AGA GGA AU   A 
Neisseria menigitidis                     CAA   AGA GGA AU   A 
Noctoc sp                                 CAA   AGA UAG AU   A 
Pseudomonas Fluorescens                   CAA   AGA CGA AU   A 
Porphyromonas gingivalis                  UAA   AGA UAA AU   A 
Prochlorococcus marinus                   CAA   AGA UAG AU   A 
Rickettsia prowazekii                     CAA   AGA UAA AU   A 
Salmonella typhi                          CAA   AGA UGA AU   A 
Salmonella typhimurium                    CAA   AGA UGA AU   A 
Streptococcus pneumoniae                  CAA   AGA CAG AU   U 
Streptococcus pyogenes                    CAA   AGA CAG AU   U 
Thermotoga Maritima                       CAA   AGA UUG AU   G 
Thermus thermophilus                      CAA   AGA GAG AU   G 
Treponema pallidum                        CAA   AGA CAG AU   U 
Vibrio cholera                            CAA   AGA GGA AU   G 
Yersinia pestis                                                          CAA   AGA GGA AU       A             
a Sequences at J5/15 and J18/2 helices of P RNA were obtained from the RNase 
P database (37). The 319 nucleotide at the J18/2 helix from 40 bacterial P RNA 
genes is highlighted in yellow.  
b Bioinformatics analysis of the N(-2) sequence preferences of the 5’ leader from 
40 bacterial pre-tRNA genes that were obtained from Genebank (38,39). 
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CHAPTER 3 
CLONING, EXPRESSION AND PURIFICATION OF HUMAN mtRNASE P 
PROTEINS 
 
Background 
 
    Ribonuclease P (RNase P) is an essential enzyme that cleaves the 5’ end of 
the precursor tRNA (pre-tRNA) to form a mature tRNA and 5’ leader (1). All  well-
characterized RNase P enzymes to date are ribozymes, composed of a large 
catalytic RNA subunit (~400 nucleotides) that associates with one or more 
proteins in bacteria, archea and eukaryotes (2-4). In bacteria, the single RNase P 
protein reconstitutes with the RNase P RNA (P RNA) to strengthen the affinity of 
RNase P for substrates, to stabilize the RNase P holoenzyme complex, and to 
reduce the dependence of activity on the salt concentration as required for in vivo 
activity (5-9). However, the bacterial, archeal and eukaryal RNase P RNAs are 
homologous and proposed to be structurally related.  Furthermore, the P RNA 
from bacteria and archea readily catalyzes cleavage of the 5’ leader in the 
absence of protein under high salt conditions in vitro (1,10,11). Hence, RNase P 
was proposed as a universally conserved ribonucleoprotein retained from the 
primordial RNA world.  
    Unlike the RNA-dependent RNase P, human mitochondrial and spinach 
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chloroplast RNase Ps have been proposed to be protein-based enzymes 
because their densities are similar to protein rather than to RNA and their 
activities are insensitive to micrococcal nuclease treatment (12-15). However, a 
protein-based RNase P remained elusive to purification.  In fact, the yeast 
mitochondrial RNase P is a protein-RNA complex (16,17) and one attempt at 
purification of the human mitochondrial RNase P suggested that the nuclear 
RNase P fulfilled this role (18).  However, Rossmanith and colleagues recently 
discovered protein subunits containing RNase P activity purified from human 
mitochondria and Arabidopsis thaliana chloroplast; recombinant expression of 
these subunits in bacteria confirmed that these organellar RNase P are 
composed of proteins (19,20). These data suggest that the newly identified 
human mitochondrial RNase P is composed of three protein subunits (MRPP1, 
MRPP2 and MRPP3) that are nuclear encoded and imported into the 
mitochondria. These proteins were isolated and identified by a combination of 
partial protein purification, mass spectrometry and enzymatic activity approaches. 
The three protein subunits appear to have distinct functionalities and Rossmanith 
and colleagues demonstrated that the complex reconstituted from recombinant 
subunits catalyze the cleavage of the 5’ end of (mt)pre-tRNA. In contrast, similar 
experiments to identify the chloroplast RNase P suggest that only a single 
subunit (PROP1, homologous to MRPP3) is essential for catalytic activity (19). 
    MRPP1 (RG9MTD1) is annotated as a RNA (guanosine-9-) methyltransferase 
domain that is homologous to yeast TRM10. Trm10p is a tRNA m1G 
methyltransferases that catalyzes N1 methylation of guanosine at position 9 of 
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tRNA using S-adenosyl methionine as a co-substrate (21). Unpublished data 
suggests that MRPP1 catalyzes the methylation of G9 of human (mt)tRNAs 
(Holzmann J and Rossmanith W, unpublished data), Therefore, MRPP1 is 
proposed to function as a m1G methyltransferase (20). Methylation of pre-tRNA 
could enhance the recognition of substrates by RNase P; however, the RNase P 
assays to date did not use methylated (mt)pre-tRNA substrates and no SAM was 
added to the assays. MRPP2 (HSD17B10) is a short-chain 
dehydrogenase/reductase that catalyzes β-oxidation of steroid and fatty acid 
substrates using NAD+ as a co-substrate (22). This enzyme also belongs to the 
short chain dehydrogenase/reductase (SDR) family with a NAD+ domain 
(Rossmann fold) that has been proposed to bind RNA (23-25). The third subunit, 
MRPP3 is a member of a novel domain family that is predicted to have metal-
dependent nuclease activity (20). Sequence alignments of MRPP3 protein 
homologs indicate two pentatricopeptide repeat (PPR) motifs and four strictly 
conserved amino acids (3 aspartates and 1 histidine) that have been proposed to 
bind RNA and metal ions, respectively (20,26,27). Furthermore, the recently 
identified Arabidopsis thaliana RNase P, PRORP1, is an ortholog to MRPP3 (19). 
These data suggest that MRPP3 is a member of a new family of metal-
dependent ribonucleases. However, the role of each of the proposed human 
mtRNase P subunits in catalysis is poorly understood. Additionally, the catalytic 
mechanism and the molecular recognition of this protein-based RNase P enzyme 
remain to be elucidated. 
    To investigate the roles of MRPP1, MRPP2 and MRPP3 in the human 
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mtRNase P catalysis, these proteins were individually cloned, recombinantly 
expressed and purified from Escherichia coli (E. coli) cells. This chapter will 
describe the cloning, expression and purification of the human mtRNase P 
subunits. The cDNA for these proteins was purchased from the American Type 
Culture Collection (ATCC), subcloned into the JEJ494 and pETM11 vectors and 
his-tagged versions of the proteins expressed in E. coli cells. Immobilized metal 
affinity (IMAC) and anion-exchange chromatography were employed to purify 
each of the subunits to reconstitute the human mtRNase P protein complex. 
Materials and Methods 
 
Subcloning of each of the human mtRNase P subunits 
MRPP2 (cat. No. MGC-8345) and MRPP3 (cat. No. MGC-36741) cDNA clones 
were purchased from ATCC. The coding sequences of the putative MRPP2 were 
amplified using the polymerase chain reaction (PCR) with 0.004U/µL PfuTurbo® 
DNA polymerase, 0.2mM dNTP mix, 10x reaction buffer (Stratagene) and the 
following primers (0.4 µM) (forward primer, FP and reverse primer, RP): FP 5’ 
GGG CCA TAT GGC AGC AGC GTG TCG G 3’, RP 5’ GGG CTC GAG TCA 
AGG CTG CAT ACG 3’ (purchased from IDT). The PCR reaction cycle was as 
the following: (a) In the first cycle, the reaction was heated to 94oC for 30 sec. (b) 
In the second cycle, the reaction was heated to 94oC for 30 sec and annealed at 
55oC for 30 sec followed by elongation at 72oC for 2 min. The second cycle was 
repeated for 26 times. (c) In the third cycle, reaction was heated to 94oC for 30 
sec and annealed at 55oC for 30 sec followed by elongation at 72oC for 11 min. 
MRPP2 PCR product and the pETM11 vector were both digested with NdeI and 
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XhoI restriction enzymes at unique restriction sites (New England Biolab, NEB). 
The MRPP2 gene was ligated to the pETM11 using the final concentration of 1X 
T4 DNA ligase buffer, 400U T4 DNA ligase (NEB), and 1:3 and 1:6 ratio of 
vector:insert in the 20 uL ligation reaction. The ligation reaction was incubated on 
ice overnight and transformed into the SmartCells™ (Genlantis) the following day. 
There are two NdeI sites in the MRPP3 sequence therefore site-directed 
mutagenesis was performed to remove the two NdeI sites (C to T at nucleotide 
564 and 1680), while retaining the MRPP3 amino acid in sequence. PCR was 
performed on the MRPP3 gene by using 0.004U/µL Taq polymerase, 0.2 mM 
dNTP mix, 10x reaction buffer (Stratagene) and the following primers (0.4 µM); 
FP 5’ GGA ACC AGC AGC ATA TGT TTT CTC TTA AAA CAA TGT CTC C 3’, 
RP 5’ GAG GTC AGA ACT CGA GTC ATG TCT TTT GGT GGA GGC 3’. The 
MRPP3 PCR product was ligated to pCR®4-TOPO® vector using the TOPO TA 
cloning® kit (Invitrogen). The PCR cycle used for MRPP3 was same as the PCR 
cycle for cloning MRPP2 gene. Both the ligated MRPP3 gene and the pETM11 
vector were double digested with NdeI and XhoI restriction enzymes followed by 
ligation with Quick T4 DNA Ligase (NEB) as described in the Quick T4 DNA 
Ligase kit. The ligated reaction was transformed into SmartCells™. The plasmids 
encoding MRPP2 (pMR2-TEV-His) and MRPP3 (pMR3-TEV-His) were purified 
and the correct gene sequence confirmed by sequencing at the Michigan DNA 
Sequencing Center. A plasmid encoding recombinant MRPP1 (pMR1-3C-His) 
was a gift from Dr. Jane Jackman (Ohio State University) and is composed of an 
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N-terminal 6x His-tag, followed by a 3C protease cleavage site and then amino 
acids 40 to 403 of MRPP1, deleting a putative mitochondrial imported sequence. 
Expression of human mtRNase P protein subunits 
The MRPP1 plasmid (pMR1-3C-His) was transformed into BL21(DE3)pLysS E. 
coli and  the cells grown in Luria broth (LB) media at 37oC to an OD600 ~ 0.8.  
Protein expression was induced by the addition of 1 mM isopropylthio-β-D-
galactopyranoside (IPTG) and incubation at 16oC overnight. Plasmids encoding 
MRPP2 (pMR2-TEV-His) and MRPP3 (pMR3-TEV-His) were transformed into 
the Rosetta(DE3) E. coli strain (Novagen) and grown in the LB media at 37oC to 
an OD600 ~ 0.8.  Protein expression was induced by the addition of 1 mM IPTG 
and incubation at 16oC overnight. The cells expressing MRPP1 and MRPP2 
were resuspended in lysis buffer (20 mM Tris-HCl  pH 7.5, 15% glycerol, 150 mM 
NaCl, 30 mM imidazole, 0.1 mM TCEP, 0.02% Tween 20, 0.1% proteinase 
inhibitor cocktail (Thermo Scientific) and 0.3 mg/mL phenylmethylsulfonyl fluoride 
(PMSF)).  Cells expressing MRPP3 was resuspended in the same lysis buffer 
with 20 mM MOPs (pH 7.8) substituted for 20 mM Tris-HCl (pH 7.5). The 
resuspended cells were frozen at -80oC until ready to be purified. 
Purification of recombinant MRPP1, MRPP2 and MRPP3 
Cells expressing MRPP1, MRPP2 or MRPP3 were lysed by sonication and 
centrifuged at 16 000g for 30 minutes for clarification of the cell lysate. The 
cleared lysate was applied to an IMAC column (GE healthcare) that was charged 
with 50 mM NiSO4. About 1 mL of IMAC resins for 1 L culture was used and the 
cleared lysate was run through the Ni(II)-charged column. The MRPP1 and 
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MRPP2 subunits were eluted using a linear gradient from 30 mM to 500 mM 
imidazole in buffer A (20 mM Tris-HCl pH 7.5, 15% glycerol, 150 mM NaCl, 0.1 
mM TCEP and 0.02% Tween 20). MRPP3 was eluted with linear gradient from 
30 mM to 300 mM imidazole with the buffer A containing 20 mM MOPS (pH 7.8), 
replacing the Tris-HCl (pH 7.5). About 1000 U of 6x His-tagged TEV protease 
(ProTEV Plus from Promega) was added to the MRPP2 and MRPP3 proteins, 
while about 500 U of 6x His-tagged 3C protease (Novagen) was added to the 
MRPP1 protein. The protease cleavage reactions were dialyzed against buffer A 
at 4oC overnight. The cleaved proteins were applied to a second Ni-IMAC column; 
the his-tagged proteases and proteins and nucleic acids that interact non-
specifically with the nickel resin should be retained on the column while the 
cleaved proteins should elute in the flow-through. MRPP3 was further purified 
using an anion or cation-exchange chromatography (DEAE or SP column from 
GE healthcare). MRPP3 was dialyzed against buffer B (20 mM MOP pH 7.8, 
15% glycerol, 50 mM NaCl and 0.1 mM TCEP) at 4oC overnight. ~ 0.1 mg/mL 
MRPP3 protein (10 mL of volume) was applied to a 5 mL DEAE column and 
eluted using a linear gradient from 50 mM and 500 mM NaCl. For the SP column, 
the MRPP3 was dialyzed in buffer C (20 mM Tris-HCl pH 7.5, 15% glycerol, 150 
mM NaCl and 0.1 mM TCEP) at 4oC overnight. ~ 1 mg/ mL of MRPP3 (15 mL of 
volume) was loaded onto the 5 mL SP column followed by elution with a linear 
gradient from 150 mM to 2 M NaCl. The MRPP proteins were concentrated using 
Vivopore concentrator or Ficoll treatment before EDTA dialysis. 
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To chelate co-eluting divalent metal ions, 0.7 mg/mL of MRPP1 (2.5 mL of 
volume) and 0.1 mg/mL of MRPP2 (2 mL of volume) were dialyzed once against 
1 L of buffer C containing 1 mM EDTA, while 0.05 mg/mL of MRPP3 (3 mL of 
volume) was dialyzed once against 1 L of buffer D (30 mM MOP pH 7.8, 15% 
glycerol, 150 mM NaCl, 0.1 mM TCEP and 1 mM EDTA) at 4oC overnight.  The 
recombinant proteins were further dialyzed once against 1 L of metal free buffer, 
that was pre-incubated with CHELEX®100 resins (Bio-Rad) without EDTA at 4oC 
overnight. The concentration of metal ions associated with each recombinant 
protein was determined by inductively coupled plasma mass spectrometry (ICP-
MS) at the Department of Geological Sciences by Dr. Ted Hudson. 
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Results 
 
cDNA clones of MRPP1, MRPP2 and MRPP3 
The MRPP1 cDNA construct, subcloned into the JEJ494 vector, is composed of 
an N-terminal His6-tag, a 3C protease cleavage site followed by the coding 
region of MRPP1 encoding amino acids 40 to 403 (the mitochondrial signaling 
sequence at the N-terminus of MRPP1 is removed, see Figure 3-1A). cDNA 
constructs of the MRPP2 and MRPP3 genes are cloned into the pETM11 vector. 
The MRPP2 and MRPP3 genes are composed of 783 and 1749 nucleotides, 
respectively, encoded between the NdeI and XhoI restriction sites of the pETM11 
vector. Recombinant MRPP2 is comprised of an N-terminal 6x His-tag and a 
TEV-protease cleavage site followed by the full length coding sequence of 
MRPP2 (Figure 3-1B). Recombinant MRPP3 has an N-terminal 6x His-tag 
followed by a TEV-protease cleavage site and amino acid 46 to 583 (Figure 3-
1C). The first 45 amino acids of MRPP3 encoding the mitochondrial signal 
localization sequence is removed.  
Recombinant expression of MRPP1, MRPP2 and MRPP3 in E. coli cells 
Recombinant MRPP1, MRPP2 and MRPP3 are expressed in the E. coli cells 
transformed with the respective T7 expression plasmid (2.5 to 6 mg protein/L cell 
culture). Overexpression of each of these proteins in E. coli cells was confirmed 
using His-tag western blot analysis (Figure 3-2B, Figure 3-5D and Figure 3-7C). 
The 45 kDa MRPP1 protein is solubly expressed in both BL21(DE3)pLysS and 
BL21(DE3) cells at 180C upon induction with 1 mM IPTG. The His-tag western 
blot analysis of MRPP1 indicates some protein degradation (Figure 3-2B). 
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A. 
MAHHHHHHMGTLEAQT(Q/G)PGSMSSKIPAVTYPKNESTPPSEELELDKWKTT
MKSSVQEECVSTISSSKDEDPLAATREFIEMWRLLGREVPEHITEEELKTLMEC
VSNTAKKKYLKYLYTKEKVKKARQIKKEMKAAAREEAKNIKLLETTEEDKQKNFL
FLRLWDRNMDIAMGWKGAQAMQFGQPLVFDMAYENYMKRKELQNTVSQLLE
SEGWNRRNVDPFHIYFCNLKIDGALHRELVKRYQEKWDKLLLTSTEKSHVDLFP
KDSIIYLTADSPNVMTTFRHDKVYVIGSFVDKSMQPGTSLAKAKRLNLATECLPL
DKYLQWEIGNKNLTLDQMIRILLCLKNNGNWQEALQFVPKRKHTGFLEISQHSQ
EFINRLKKAKT 
 
B. 
MKHHHHHHPMSDYDIPTTENLYFQ(G/H)MAAACRSVKGLVAVITGGASGLGLA
TAERLVGQGASAVLLDLPNSGGEAQAKKLGNNCVFAPADVTSEKDVQTALALA
KGKFGRVDVAVNCAGIAVASKTYNLKKGQTHTLEDFQRVLDVNLMGTFNVIRLV
AGEMGQNEPDQGGQRGVIINTASVAAFEGQVGQAAYSASKGGIVGMTLPIARD
LAPIGIRVMTIAPGLFGTPLLTSLPEKVCNFLASQVPFPSRLGDPAEYAHLVQAII
ENPFLNGEVIRLDGAIRMQP  
 
C. 
MKHHHHHHPMSDYDIPTTENLYFQ(G/H)MFSLKTMSPQNTKATNLIAKARYLRK
DEGSNKQVYSVPHFFLAGAAKERSQMNSQTEDHALAPVRNTIQLPTQPLNSEE
WDKLKEDLKENTGKTSFESWIISQMAGCHSSIDVAKSLLAWVAAKNNGIVSYDL
LVKYLYLCVFHMQTSEVIDVFEIMKARYKTLEPRGYSLLIRGLIHSDRWREALLLL
EDIKKVITPSKKNYNDCIQGALLHQDVNTAWNLYQELLGHDIVPMLETLKAFFDF
GKDIKDDNYSNKLLDILSYLRNNQLYPGESFAHSIKTWFESVPGKQWKGQFTTV
RKSGQCSGCGKTIESIQLSPEEYECLKGKIMRDVIDGGDQYRKTTPQELKRFEN
FIKSRPPFDVVIDGLNVAKMFPKVRESQLLLNVVSQLAKRNLRLLVLGRKHMLR
RSSQWSRDEMEEVQKQASCFFADDISEDDPFLLYATLHSGNHCRFITRDLMRD
HKACLPDAKTQRLFFKWQQGHQLAIVNRFPGSKLTFQRILSYDTVVQTTGDSW
HIPYDEDLVERCSCEVPTKWLCLHQKT    
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Figure 3-1: Protein sequences of the three human mtRNase P subunits encoded 
in the JEJ494 and pETM11 vectors. (A) Sequence of the MRPP1 protein 
encoded by the pMR1-3C-His plasmid with the 6x His-tag highlighted in yellow, 
the 3C protease cleavage site sequence in red and the MRPP1 protein sequence 
from amino acid 40 to 403 underlined. (B) Sequence of the MRPP2 protein 
encoded by the pMR2-TEV-His plasmid with the 6x His-tag highlighted in yellow, 
TEV protease cleavage site sequence in green and the MRPP2 full length protein 
sequence underlined the TEV protease cleavage site sequence in green and the 
protein sequence underlined. (C) Sequence of the MRPP3 protein encoded by 
the pMR3-TEV-His plasmid with the 6x His-tag highlighted in yellow, TEV 
protease cleavage site sequence in green and the MRPP3 protein sequence 
starting from amino acid 46 to 583 underlined.  
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cells compared to BL21(DE3) pMR1-3C-His plasmid cells (Figure 3-2). To reduce 
the protein degradation by the cellular proteases, the temperature for expression 
of MRPP1 in BL21(DE3)pLysS pMR1-3C-His cells was lowered to 16°C since 
this decreases the proteolytic activity in E. coli cell lysates  (28).  
    To optimize recombinant expression of the 28 kDa MRPP2 in E. coli the media 
(auto-induction and LB media), IPTG concentration (0 to 400 µM) and cell lines 
(BL21(DE3) and Rosetta(DE3) cells) were varied using the 96 well-plates. To 
evaluate expression levels of MRPP2, the cells were induced, incubated at 280C 
overnight, pelleted and then lysed by addition of the B-Per II bacterial protein 
extraction reagent (Thermo Scientific). The soluble and insoluble proteins were 
separated by centrifugation and fractionated on by SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) (Figure 3-3). These data illustrate that the 
expression level of the MRPP2 is unaffected by the cell line (Rosetta(DE3) and 
BL21(DE3) cells) (Figure 3-3A and 3-3B) or the culture medium/induction method 
(auto-induction versus LB/IPTG medium). However, the majority of the 
expressed MRPP2 is insoluble (Figure 3-3C and 3-3D). Alternatively, the 
expression level of MRPP2 can be optimized by varying temperature, from 34oC 
to 16oC to increase in the MRPP2 solubility. Currently, to obtain sufficient 
MRPP2 protein for activity measurement, the MRPP2 is grown in Rosetta(DE3) 
cells at 37oC followed by induction with 1 mM IPTG at OD600 ~0.8 and continued 
to grow at 16oC (as described in (20)).   
    The 62 kDa MRPP3 was expressed in both the BL21(DE3)pLysS and 
Rosetta(DE3) cells, induced by addition of 1 mM IPTG and incubation for 16 to 
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18 hr at 16°C followed by SDS-PAGE analysis. Based on the SDS-PAGE 
analysis, the MRPP3 has higher expression level in the Rosetta(DE3) cells 
relative to BL21(DE3)plysS cells (Figure 3-5A and 3-5B). To examine the 
expression levels of MRPP3 in Rosetta(DE3) cells, the cells were induced, 
incubated at 160C overnight, pelleted and then lysed by addition of the B-Per II 
bacterial protein extraction reagent (Thermo Scientific). The soluble and insoluble 
proteins were separated by centrifugation and fractionated on by SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 3-4). These data 
illustrate that the expression level of MRPP3 does not increase after induction 
with 1 mM IPTG for 4 to 20 hr (Figure 3-4A) and MRPP3 protein is not in the 
insoluble form as well (Figure 3-4B). This could be due to the toxicity of the 
MRPP3 protein toward E. coli cells and cause cells death.  
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Figure 3-2: SDS-PAGE and Western blot analysis of recombinant expression of 
MRPP1 protein. (A) Expression level of MRPP1 (indicated by arrow) in the 
cleared lysates from BL21(DE3)pLysSpMR1-3C-His and BL21(DE3)pMR1-3C-
His cells. The cleared lysates are the total expression from 
BL21(DE3)pLysSpMR1-3C-His and BL21(DE3)pMR1-3C-His cells. Lanes 1 and 
2 are lysates from non-induced BL21(DE3)pLysSpMR1-3C-His cells, while lane 3 
is the lysate from non-induced BL21(DE3)pMR1-3C-His cells. Lanes 4, 5 
(duplicate samples) and 7, 8 (duplicate samples) are lysates from 
BL21(DE3)pLysSpMRP1-3C-His cells at 2 ½  and 20 hours, respectively, after 
induction with 1 mM IPTG and incubation at 18°C, correspondingly. Lane 6 and 9 
are lysates from BL21(DE3)pMR1-3C-His cells at 2 ½  and 20 hours, respectively, 
after induction with 1 mM IPTG and incubation at 18°C, respectively. (B) His-tag 
western blot analysis of MRPP1 expressed in the lysates of 
BL21(DE3)pLysSpMR1-3C-His and BL21(DE3)pMR1-3C-His cells. The samples 
loaded in lanes 1 to 9 correspond to the samples in lanes 1 to 9 in (A).  
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Figure 3-3: Level of MRPP2 (shown by red star) expression in BL21(DE3) and 
Rosetta(DE3) cells transformed with pMR2-TEV-His as indicated by fractionation 
on a SDS-PAGE gel. (A) Expression level of soluble MRPP2 in cell lysates from 
Rosetta(DE3)pMR2-TEV-His cells grown in auto-induction or LB media with 
varied IPTG concentrations at 28°C. Lane 1 is the lysate from non-induced cells, 
while lanes 2, 3, and 4 contain the lysates from Rosetta(DE3)pMR2-TEV-His 
cells induced with 50, 100 and 400 µM IPTG, respectively, in LB media while 
lane 5 is from the lysate from cells grown in auto-induction media. (B) The 
samples loaded onto the SDS-PAGE gel are the same as those in panel (A) 
except that the cell line is BL21(DE3)pMR2-TEV-His. (C) Expression level of the 
insoluble MRPP2 protein in Rosetta(DE3) cells.  The samples loaded onto the 
SDS-PAGE gel are taken from the same cell growths as panel (A) but here the 
insoluble fraction is loaded onto the gel, rather than the soluble fraction shown in 
(A). (D) Same as (B) with exception that the insoluble fraction is loaded onto the 
gel. 
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Figure 3-4: Level of MRPP3 (shown by arrow) expression in Rosetta(DE3) cells 
transformed with pMR3-TEV-His as indicated by fractionation on a SDS-PAGE 
gel. (A) Expression level of soluble MRPP3 in cell lysates from 
Rosetta(DE3)pMR3-TEV-His cells grown in LB media at 16oC. Lane 1, 2, and 3 
are the soluble MRPP3 from non-induced cells, while lanes 4, 5, and 6 contain 
the lysates from Rosetta(DE3)pMR3-TEV-His at 4 hr after induction with 1 mM 
IPTG and incubation at 16°C. Lanes 7, 8, and 9 contain the lysates from 
Rosetta(DE3)pMR3-TEV-His at 20 hr after induction with 1 mM IPTG and 
incubation at 16°C. (B) Expression level of insoluble MRPP3 in cell lysates from 
Rosetta(DE3)pMR3-TEV-His cells grown in LB media at 16oC. The samples 
loaded onto the SDS-PAGE gel are the same as those in panel (A) except that 
the MRPP3 protein is insoluble. 
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Figure 3-5: SDS PAGE analysis of MRPP3 (shown by arrow) protein purification 
from recombinant expression in either Rosetta(DE3)pMR3-TEV-His or 
BL21(DE3)pLysSpMR3-TEV-His cells. (A) SDS PAGE analysis of MRPP3 
expressed in BL21(DE3)pLysSpMR3-TEV-His cells and fractionation using a 
Ni(II)-Chelating Sepharose with an imidazole gradient. Lane 1 is the cleared 
cellular lysate containing soluble MRPP3 that is loaded onto the column and 
lanes 2 and 3 are flow-through and first wash of the column. Lanes 4 to 14 show 
the protein elution profile; MRPP3 elutes from the Ni(II) column mainly in lanes 6 
- 10. B) SDS PAGE analysis of MRPP3 expressed in Rosetta(DE3)pMR3-TEV-
His cells and fractionation using a Ni(II)-Chelating Sepharose with an imidazole 
gradient. Lane 1 is the cleared cellular lysate containing soluble MRPP3 that is 
loaded onto the column and lane 2 is the flow-through from the column. Lanes 3 
to 11 show the protein elution profile; MRPP3 elutes from the Ni(II) column 
mainly in lanes 4 – 6, although multiple bands are observed in this eluate. (C) 
SDS-PAGE analysis of MRPP3 from (A) after cleavage by TEV protease and 
fractionation on a second Ni(II) column. Lane 1 is the His-tagged MRPP3 before 
cleavage with TEV protease and Lane 2 is MRPP3 after cleavage and 
purification on a second Ni(II) column.  This protein is estimated as 90% pure. 
(D) His-tag western blot analysis of MRPP2 and MRPP3 expressed in the lysates 
of Rosetta(DE3)pMR2-TEV-His and BL21(DE3)pLySpMR3-TEV-His cells. Lane 1 
and 2 are MRPP2 protein (shown by red star) that serves as a positive control for 
His-tag western blots. Lane 3 is soluble MRPP3 protein and lane 4 is MRPP3 
protein after first Ni(II) column. 
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Purification of MRPP1, MRPP2 and MRPP3 proteins 
 
The His-tagged MRPP1, MRPP2 and MRPP3 proteins are purified using IMAC 
affinity chromatography with Chelating Sepharose matrix charged with NiSO4. 
The His-tagged MRPP1, MRPP2 and MRPP3 each elute from the Ni(II)-charged 
IMAC column at about 100 mM imidazole.  After proteolytic cleavage of the his-
tag and purification using a second Ni(II)-IMAC column, MRPP1 and MRPP2 are 
~95% pure, while the MRPP3 is > 90% pure based on SDS-PAGE analysis  
(Figure 3-6B, 3-7B, and 3-5C). The purified MRPP1, MRPP2 and MRPP3 contain 
a cleavable His-tag and are cleaved with the 3C and TEV proteases, respectively. 
The 3C protease cleaves the MRPP1 with ~ 90% efficiency, while the TEV 
protease cleaves the MRPP2 and MRPP3 with ~ 50% efficiency (Figure 3-6B, 3-
7B and 3-5C).  
For purification of MRPP3, precipitation observed when the protein is 
concentrated using the Amicon Ultra centrifugal filters. Therefore, gentle methods 
to concentrate the protein, such as Vivapore concentrator or Ficoll treatment is 
necessary.  Additionally, the 260 nm/280 nm absorbance ratio of the MRPP3 
protein was ~1.0, suggesting that nucleic acids co-eluted with this protein. 
Therefore, MRPP3 was further purified using either anion (DEAE-Sephacel™ 
Fast Flow) or cation (SP-Sepharose™ Fast Flow) exchange chromatography 
with a salt gradient to remove contaminating proteins and nucleic acids (Figure 3-
8).  MRPP3 is eluted from the DEAE and SP columns at ~150 mM NaCl and 700 
mM NaCl, respectively. The DEAE column successfully removes nucleic acids, 
as indicated by a decrease in the 260/280 nm absorbance ratio of MRPP3 to 0.8.  
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However, after the SP column the 260/280 nm absorbance ratio of MRPP3 
remains at ~ 1.0, suggesting that nucleic acids co-elute with MRPP3. After cation 
exchange chromatography the purity of MRPP3 is estimated as 95%. The activity 
measurement of the purified MRPP proteins will be alluded to Chapter 4. 
 
 
 
 
 
 
 
 
 
Figure 3-6: Purification of His-tagged MRPP1 by affinity chromatography. (A) 
SDS-PAGE analysis of MRPP1 fractionation on a Ni(II)-charged IMAC column. 
The His-tagged MRPP1 protein is applied to the Ni(II) column in 20 mM Tris-HCl 
pH 7.5, 15% glycerol, 150 mM NaCl, 0.1 mM TCEP, 30 mM imidazole buffer and 
0.02% Tween 20 and is eluted with linear gradient from 90 to 500 mM imidazole. 
Lane 1 is molecular mass standards. MRPP1 (shown by the arrow) elutes from 
the NI(II) column upon addition of 90 mM imidazole (fractions 1 to 27). (B) The 6x 
His-tag attached to purified MRPP1 is cleaved by incubation with 3C protease. 
Lane 1 is the His-tagged MRPP1 before cleavage and lane 2 is the cleaved 
MRPP1 protein after purification on the second Ni(II) column. 
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Figure 3-7: Purification of MRPP2 protein by Ni(II)-charged IMAC column. (A) 
SDS-PAGE analysis of MRPP2 fractionation on a Ni(II)-charged IMAC column. 
The His-tagged MRPP2 protein is applied to the Ni(II) column in 20 mM Tris-HCl 
pH 7.5, 15% glycerol, 150 mM NaCl, 0.1 mM TCEP, 30 mM imidazole and 0.02% 
Tween 20 buffer and is eluted with linear gradient from 100 to 500 mM imidazole. 
Lanes a and b are the protein flow-through and wash-flow-through of the column, 
respectively. MRPP2 (shown by the arrow) elutes from the NI(II) column at the 
start of the imidazole gradient (100 mM) (fractions 1 to 31). (B) The 6x His-tag 
attached to purified MRPP2 is cleaved by incubation with TEV protease. Lane 1 
is the His-tagged MRPP2 before cleavage and lane 2 is the cleaved MRPP2 
protein after purification on the second Ni(II) column. (C) His-tag western blot 
analysis of MRPP2 expressed in the lysates of Rosetta(DE3)pMR2-TEV-His cells. 
MRPP2 indicated in arrow is the total expression of MRPP2 after 18 hr induction 
by 1 mM IPTG at 16oC. 
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Figure 3-8: SDS PAGE analysis of MRPP3 protein fractionated by DEAE and SP 
column chromatography using a linear salt gradient. (A) MRPP3, shown by the 
star, is eluted from the DEAE column at ~150 mM NaCl in 20 mM MOPS pH 7.8, 
15% glycerol, and 0.1 mM TCEP buffer. (B) Purification of MRPP3 using SP 
chromatography. Lane 1 is the MRPP3 protein after the first Ni(II) column and 
before applied to the SP column, lane 2 is the protein flow-through from the SP 
column and lanes 3 to 9 are the eluate fractions containing MRPP3 (~700 mM 
NaCl). 
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Discussion 
 
    The cDNAs encoding the MRPP1, MRPP2 and MRPP3 genes were sub-
cloned into E. coli expression vectors with the addition of a His-tag and removal 
of mitochondrial localization sequences and recombinantly expressed in the E. 
coli cells. The MRPP1 expression is higher in the BL21(DE3)pLysS cells 
compared to BL21(DE3) cells transformed with the expression plasmid. This 
result suggests that expression of MRPP1 in E. coli affects cell growth and/or 
viability. MRPP1 expression is enhanced in the BL21(DE3)pLysS cells because 
the T7 lysozyme expressed from the pLysS plasmid inhibits T7 RNA polymerase 
to suppress the basal expression level of MRPP1 before IPTG induction (29).  
MRPP2 expresses well in the Rosetta(DE3)pMR2-TEV-His cells, however, 
the majority of the MRPP2 protein is insoluble when growing at 28oC. However, 
Rossmanith and coworkers, have grown the MRPP2 protein at 16oC. Therefore, 
to obtain sufficient MRPP2 protein for the experiments carried out in Chapter 4, 
the pMR2-TEV-His plasmid was transformed and grown in the Rosetta(DE3) 
cells at 37oC followed by induction with 1 mM IPTG at OD600 ~0.8 and continued 
to grow at 16oC (Figure 3-7). In the future, soluble expression of recombinant 
MRPP2 could be enhanced by attaching a solubility-enhancing tag, such as 
SUMO, MBP or GST tag, to the N-terminus of the pMR2-TEV-His plasmid 
(30,31). Recombinant expression of MRPP3 is enhanced in the 
Rosetta(DE3)pMR3-TEV-His cells relative to BL21(DE3)pLysSpMR3-TEV-His 
cells. The Rosetta(DE3) cell line contains a plasmid containing “rare” tRNA 
genes that encode eukaryotic codons rarely used in the E. coli (31). The “rare” 
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tRNA genes can increase the expression level of the eukaryotic proteins by 
raising the concentrations of tRNAs that recognize the eukaryotic codon usage 
during protein translation in E. coli. Codon usage frequency analyzer indicate 11 
out of 50 codons in the 5’ end of the MRPP3 mRNA score low codon usage (< 
20%) by the E. coli (Figure 3-9). Therefore, expression of Rosetta(DE3)pMR3-
TEV-His cells with “rare” tRNA will support the transcription initiation of the 
MRPP3 mRNA (32). This phenomenum could explain the higher expression level 
of MRPP3 in the Rosetta(DE3) cells. 
    The His-tagged MRPP1, MRPP2 and MRPP3 proteins are each purified using 
IMAC affinity chromatography and MRPP3 is further purified using either anion or 
cation exchange chromatography. MRPP1, MRPP2 and MRPP3 each elute from 
the Ni(II) affinity column at ~100 mM imidazole with ≥ 70% purity. The His-tag 
attached to MRPP1, MRPP2, and MRPP3 is each cleaved by incubation with 3C 
or TEV protease with ≥ 50% efficiency. A second Ni(II) column is used to 
separate the non-cleaved and cleaved MRPP1, MRPP2 and MRPP3 proteins as 
well as to remove the His-tagged proteases and other proteins that bind 
nonspecifically to the resin; the cleaved proteins do not bind to the Ni(II) column. 
Since MRPP3 has a calculated pI of ~ 9 (33) and is a proposed to bind nucleic 
acids, this protein is further purified using ion exchange chromatography (DEAE-
Sephacel™ Fast Flow)  to eliminate contaminating nucleic acids. 
   In summary, MRPP1, MRPP2 and MRPP3 are three distinct proteins that are 
transported to the mitochondrial via the signal localization sequences and are 
proposed to form a complex that catalyzes cleavage of mitochondrial precursor 
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tRNAs in human mitochondria  (20). The function of each of the MRPP1, MRPP2 
and MRPP3 subunits in the human mtRNase P complex for catalysis of pre-tRNA 
is unclear and remains to be determined. Previous data suggested showed that 
the reconstituted human mtRNase P protein complex catalyzes cleavage of the 5’ 
end of the (mt)pre-tRNA in a 2:4:1 ratio of MRPP1:MRPP2:MRPP3. However, 
the exact stoichiometry of the subunits in human mtRNase P protein complex 
needs to be clarified. To further explore the catalytic function of human mtRNase 
P each of the subunits was recombinantly expressed in E. coli and purified using 
IMAC and anion exchange chromatography. These proteins were successfully 
expressed in E. coli cells at a level of 2.5 – 6 mg protein/L culture medium.   
Each of these recombinant proteins was successfully purified to >95% purity 
using affinity and anion-exchange chromatography. This work has developed 
methods to produce quantities of pure, recombinant MRPP1, MRPP2 and 
MRPP3 to investigate the catalytic mechanism of human mtRNase P in 
processing the (mt)pre-tRNA, as described in Chapter 4. Further optimization of 
expression levels in the future will enhance the biochemical and structural 
studies of these proteins.   
Prior studies have shown that point mutations in the human (mt)tRNAs 
have been associated with human mitochondrial dysfunction, such as 
mitochondrial myopathy, encephalopathy, lactic acidosis and stroke (MELAS) 
syndrome (34,35). Some of these (mt)pre-tRNA point mutations decrease the 
cleavage efficiency of the human mtRNase P (36). Furthermore, mutations in 
MRPP3 have been associated with myocardial infarction and coronary artery 
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disease (37). Hence, elucidating the catalytic mechanism and substrate 
recognition by the human mtRNase P in processing (mt)pre-tRNA will shed some 
light of how these pathogenic mutations affect the (mt)tRNA processing pathway 
and how this may contribute to pathogenesis. 
 
Figure 3-9: Codon usage frequency analyzer of MRPP3 coding sequences. The 
grey and red bars indicate the frequency of MRPP3 codon usage by E. coli that 
are < 20% and < 10%, respectively. The frequency of MRPP3 codon usage that 
will be enhanced by the “rare” tRNAs in the Rosetta(DE3) cell lines are shown in 
(*). 
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CHAPTER 4 
IDENTIFICATION OF METAL ION ACTIVATION OF HUMAN 
MITOCHONDRIAL RNASE P CATALYSIS 
 
Background 
 
Ribonuclease P (RNase P) is an endonuclease that catalyzes the 5’ end 
maturation of precursor tRNA (pre-tRNA) to form mature tRNA and 5’ leader. 
Nuclear RNase P is highly conserved in all three kingdom of life (Bacteria, 
Archaea and Eukarya) and consists of a large catalytic RNA subunit and one or 
more protein subunits in vivo (1-3). In Bacteria, the RNase P RNA alone has 
comparable activity to the RNase P holoenzyme in the presence of high 
concentrations of salts (100 mM NH4Cl and 60 mM MgCl2) (4). In the absence of 
the protein subunits, some Archeal and Eukaryal RNase P RNAs are catalytically 
active in vitro only in the presence of very high salt (least 1 M monovalent and 
160 mM divalent ions) (6,7). The RNase P protein subunits play essential roles in 
the in vivo activity of the RNase P holoenzyme, including optimizing the catalytic 
activity, enhancing affinity of pre-tRNA substrates for RNase P, stabilizing the 
RNA.protein complex, and decreasing the metal ion concentration required for 
activation of RNase P catalysis (8-12). The RNA-dependent RNase P has been 
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proposed as a remnant from the ancient RNA world.  Recently, an RNase P 
activity composed solely of protein subunits was demonstrated in both human 
mitochondria and spinach chloroplast (13,14). The newly identified 
“proteinaceous” RNase P from human mitochondrial (mtRNase P) is composed 
of three protein subunits called MRPP1, MRPP2 and MRPP3, which are not 
related to any previously known RNase P protein components (14).  The 
chloroplast RNase P (PRORP1) is suggested to require a single subunit that is 
homologous to MRPP3. 
    MRPP1 is a tRNA m1G methyltransferase, which is a homolog of Trm10p that 
catalyzes the N1 methylation of guanosine at position 9 of tRNA. 10 out of 34 S. 
cerevisiae tRNAs, including tRNAPro, tRNAGly, tRNATrp, tRNAVal, tRNAICGArg, two 
tRNAUCUArg, tRNAIle, tRNAiMet, and tRNAAla have m1G modification at position 9 of 
tRNA (14,16). MRPP2 is a member of the short-chain dehydrogenase/reductase 
family that has multiple functions in vivo (17), including isoleucine degradation, 
sex steroid and neurosteroid metabolism, and potentially related to Alzheimer’s 
Disease progression (18-21). Specifically, MRPP2 catalyzes the NAD+-
dependent oxidation of 2-methyl-3-hyroxybutryryl-CoA, a metabolite in isoleucine 
degradation, to form 2-methyl-acetoacetyl-CoA as well as the oxidation of 17β-
estradiol, a steroid hormone, to form estrone. 2-methyl-3-hyroxybutryryl-CoA 
dehydrogenase deficiency has lead to progressive infantile neurodegeneration 
(22). MRPP1 and MRPP2 form a complex and each contains a RNA binding 
motif that is proposed to function in recognition of tRNA for the mitochondrial 
RNase P (23,24). MRPP3 was annotated as a protein of unknown function. 
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Domain analysis and sequence comparisons indicate that MRPP3 has two 
pentatricopeptide repeats (PPR motifs) as well as three conserved aspartate and 
one conserved histidine residues at the C-terminus, which is a characteristic of a 
metallonuclease enzyme (14). Therefore, MRPP3 is proposed to form a novel 
metallonuclease family.  However, the catalytic function of each of the MRPP 
subunits in human mtRNase P has not yet been determined. Further 
investigation is necessary to understand how a protein-only RNase P adopts the 
functionality of RNA-mediated RNase P enzyme. The catalytic mechanism, 
requirement for metal ions and the determinants of molecular recognition in 
human mtRNase P remain to be studied. Here in Chapter 4, we will elucidate 
metal ion requirement for activating the catalytic activity of human mtRNase P, 
which is one of the important elements in the RNase P catalysis. 
    All characterized RNase P enzymes are metal-dependent, requiring 
magnesium ions to activate cleavage of a phosphodiester bond of pre-tRNA to 
form mature tRNA with a 5’-phosphate and a leader fragment with 3’-hydroxyl 
end groups (25,26).  Metal ions play multiple roles in the RNA-dependent RNase 
P.  For example, more than 100 magnesium ions interact non-specifically with 
bacterial RNase P RNA to neutralize charge repulsion between phosphates and 
to stabilize the formation of tertiary structure. Additionally, at least four specific 
magnesium binding sites stabilize RNase P RNA folding as well as ground and 
transition state interactions with pre-tRNA (27). The RNase P protein increases 
the apparent affinity of magnesium ions that are required for enhancing the 
affinity of RNase P for pre-tRNA. The enhancement of magnesium affinity is 
 99 
coupled to a conformational change that allows the 5’ leader of pre-tRNA to 
interact with the P protein subunit of RNase P (12,28,29). Hence, the protein 
subunit of RNase P protein enhances catalytic activity at physiological 
magnesium concentrations. Therefore, magnesium ions play multiple essential 
functions in the ribozyme RNase P catalysis in vivo. However, the role of metal 
ions in activating human mitochondrial RNase P is unclear. 
   Sequence comparison of MRPP3 homologs show two PPR motifs, that are 
proposed as RNA binding motifs, and eight highly conserved residues, including 
2 cysteine, 4 aspartates and 1 histidine residues, that could potentially function to 
coordinate metal ions (Figure 4-1). Based on the sequence and structure 
comparisons, bioinformatic analysis predicted that the KIAA0391 (MRPP3 gene) 
contains a NYN domain (5). The NYN domain is proposed to share a protein fold 
that is similar to two characterized nucleases, including Pilt N-terminal  (PIN) and 
FLAP/5’ 3’ exonuclease. These proteins both contain a set of four conserved 
acidic residues, such as aspartate, that coordinate one or two magnesium ions 
important for catalytic activity at the active site.  Proteins containing the NYN 
domain as well as one or more RNA binding domains, such as PPR motifs, KH, 
RRM and CCCH domains, are proposed to form a new class of nucleases. 
Therefore, in this chapter, biochemical studies are performed to determine 
whether human mtRNase P is activated by metal ions and, if so, the identity of 
the metal ions that enhance catalysis.  
    Here, we elucidate the first direct evidence that MRPP3, in the absence of the 
other two subunits, catalyzes cleavage of pre-tRNA in the presence of 1 mM 
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MgCl2, illustrating that MRPP3 is the catalytic subunit of the human mtRNase P.  
Additionally, MRPP3 catalytic activity shows a hyperbolic dependence on 
magnesium ions in the presence of cobalt hexammine indicating a minimum of 
one inner sphere magnesium binding site in MRPP3.  Furthermore, the 
stoichimetric zinc bound to MRPP3 enhances catalytic activity relative to the 0.14 
mol/mol MRPP3.  Domain analysis of MRPP3 identifies a site with homology to a 
zinc finger, suggesting a structural zinc site in MRPP3. Finally, formation of the 
MRPP1/MRPP2/MRPP3 protein complex slightly decreases the cleavage rate of 
the (mt)pre-tRNA compared to the MRPP3 alone, indicating that mitochondrial 
RNase P activity may require only the MRPP3 subunit, as suggested for the 
chloroplast enzyme (13).        
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Figure 4-1: (A) Multiple sequence alignment of metazoan, kinetoplastid, and 
angiosperm MRPP3 protein sequences. Sequences were retrieved from the 
NCBI database by iterative BLAST searches. Amino acids in red are conserved 
side chains that could be involved in inner sphere metal ion coordination. (B) 
Model of MRPP3 domains adapted from Anantharaman, V. et. al., 2006 (5). The 
PPR, CXXC and NYN domains of the MRPP3 are represented by blue, yellow 
and red colors, respectively. Pfam analysis (15) indicates two PPR motifs that is 
proposed to bind RNA, one CXXC motif, which has homology to a structural zinc 
binding domain (C348 and C351 in (A)), and  one NYN domain, where the 
conserved acidic residues are located (D409, D478, D479, and D499 in (A)). 
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Materials and Methods 
 
Precursor tRNA substrate 
The (mt)pre-tRNATyr  sequence was PCR and cloned behind a T7 RNA 
polymerase promoter in the  pGEM-1 vector (Promega) containing the 
BamHI/EcoRI restriction sites. The (mt)pre-tRNATyr was linearized using BamHI, 
transcribed in vitro using T7 RNA polymerase (ref) and purified on an 8% 
polyacrylamide (PAGE) gel. The transcribed (mt)pre-tRNATyr consists of the 
following sequence (tRNA is listed in uppercase letters, while the 5’ and 3’ trailers 
are shown in lowercase letters): 
ggattctagagaatagtcaacggtcggcgaacatcagtgggggtgaGGTAAAATGGCTGAGTGAA
GCATTGGACTGTAAATCTAAAGACAGGGGTTAGGCCTCTTTTTACCAgctccga
ggtgattttcatattgaattgcaaattggatcc. (mt)pre-tRNATyr was body labeled by incusion 
of  [α-32P]GTP in the transcription reaction  and 5’ end-labeled with [γ-32P]ATP 
(MP Biomedical) in the presence of T4 polynucleotide kinase (New England 
Biolabs). The 32P-labeled (mt)pre-tRNATyr was gel purified on an 8% PAGE gel, 
eluted overnight in elution buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.1% 
SDS and 500 mM NaCl) and extracted with an equal volume of 
chloroform/phenol followed by ethanol precipitation. 
mtRNase P proteins cloning and expression 
MRPP1 was cloned behind a T7 polymerase promoter in the JEJ494 vector with 
a 6x His-tag followed by 3C protease cleavage site at the N-terminus (gift from Dr. 
Jane Jackman). MRPP2 and MRPP3 were cloned into pETM11 vectors behind a 
T7 polymerase promoter with a 6x His-tag and a TEV protease cleavage site at 
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the N-terminus (as described in Chapter 3). The double mutation of D435 and 
D436 to alanine in MRPP3 was prepared using QuikChange site-directed 
mutagenesis (Stratagene). MRPP1 was recombinantly expressed in 
BL21(DE3)pLysS cells transformed with a plasmid encoding MRPP1, while 
MRPP2, MRPP3 and the D435A/D436A MRPP3 mutant were expressed in the 
Rosetta(DE3) (Novagen) cells containing the respective plasmids. These E. coli 
cells were grown in Luria broth (LB) media at 37oC and protein expression was 
induced by addition of 1 mM isopropylthio-β-D-galactopyranoside (IPTG) when 
OD600 = 0.8. At this time, the temperature was reduced to 16oC and the cells 
were incubated overnight. The cells were harvested by centrifugation (6000g, 15 
min at 40C) and resuspended in the lysis buffer (20 mM Tris-HCl  (pH 7.5), 15% 
glycerol, 150 mM NaCl, 30 mM imidazole, 0.1 mM TCEP, 0.02% Tween 20, 0.1% 
proteinase inhibitor cocktail (Thermo Fisher) and 0.3 mg/mL 
phenylmethylsulfonyl fluoride (PMSF)).  
mtRNase P proteins purification 
E. coli cells expressing RNase P subunits were lysed using a sonicator followed 
by centrifugation at 16 000g for 30 minutes. The cleared lysate was applied to a 
NiSO4-charged immobilized metal affinity column (Ni-IMAC; GE Healthcare) and 
washed with additional lysis buffer. His-tagged MRPP1 and MRPP2 were eluted 
by a linear gradient of 30 mM to 500 mM imidazole in buffer A (20 mM Tris-HCl 
(pH 7.5), 15% glycerol, 150 mM NaCl, 0.1 mM TCEP and 0.02% Tween 20). The 
His-tagged native and D478A/D479A mutant of MRPP3 were eluted with a 30 
mM to 300 mM imidazole gradient in buffer A where 20 mM 4-
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morpholinepropanesulfonic acid (MOPS, at pH 7.8) replaced 20 mM Tris-HCl (pH 
7.5). The 6x His-tagged 3C and TEV proteases were incubated with the purified 
His-tagged MRPP1, and  MRPP2, respectively, and the reaction was dialyzed in 
buffer B (20 mM Tris-HCl (pH 7.5), 15% glycerol, 150 mM NaCl and 0.1 mM 
TCEP) at 4oC overnight. The 6x His-tagged MRPP3 was incubated with TEV 
protease and the reaction was dialyzed in buffer C (20 mM MOPS (pH 7.8), 15% 
glycerol, 150 mM NaCl and 0.1 mM TCEP) at 4oC overnight. The cleaved 
recombinant proteins were purified using second Ni(II)-IMAC column to remove 
the 6x His-tagged proteases and any proteins that nonspecifically bind to this 
resin. MRPP3 was dialyzed in buffer D (20 mM MOPS (pH 7.8), 15% glycerol, 50 
mM NaCl and 0.1 mM TCEP) at 4oC overnight. Then MRPP3 was further purified 
using DEAE anion-exchange chromatography and was eluted using a linear 
gradient from 50 mM to 500 mM NaCl. Prior to metal analysis, MRPP1, MRPP2 
and MRPP3 were dialyzed in buffer E (30 mM MOPS (pH 7.8), 15% glycerol, 150 
mM NaCl, 0.1 mM TCEP and 1 mM EDTA) at 4oC overnight to chelate bound 
and adventitious divalent metal ions. The recombinant proteins were further 
dialyzed in the same buffer without 1 mM EDTA at 4oC overnight. The metal ions 
bound to the recombinant proteins were analyzed by inductively coupled plasma 
mass spectrometry (ICP-MS) at the Geology ICP Facility. 
 
Human mtRNase P protein complex activity assay 
    Single turnover experiments were performed using an excess concentration of 
MRPP3, and MRPP1/MRPP2/MRPP3 complex concentration ([E]/[S] >> 5; [E] ~ 
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50 nM to 440 nM; [S] ≤ 0.1 nM) with limiting radiolabelled (mt)pre-tRNATyr. The 5’ 
leader product was separated from the (mt)pre-tRNATyr substrate on a 8% 
denaturing polyacrylamide gel (PAGE) and quantified by PhosphorImager 
analysis (Amersham Bioscience Corp.). The observed rate constants, kobs were 
determined by fitting a single-exponential equation to the data (Equation 1). The 
dependence of kobs on enzyme concentration was evaluated using Equation 2. 
 
Scheme 1  
 
Equation 1     
Equation 2 kobs =
kmax[E]
K1/2 +[E]
;K1/2 =
kmax + k!1
k1
 
Equation 3   kobs =
kmax[E]
K1/2
 , assuming that K1/2 >>> [E] 
Dependence of kobs on magnesium concentration  
Single turnover cleavage of pre-tRNA was measured using excess MRPP3 and 
MRPP1/MRPP2/MRPP3 complex concentration ([E]/[S] >> 5; [E] 100 nM; [S] ≤ 
0.1 nM) with limiting 5’ end-labelled 32P-(mt)pre-tRNATyr at various concentrations 
of MgCl2 concentration (0 to 3 mM MgCl2). The 5’ leader product was separated 
from the substrate on a 8% PAGE and quantified by PhosphorImager analysis. 
The observed rate constant, kobs, at each MgCl2 concentration was obtained by 
fitting Equation 1 to the time-dependent cleavage. The magnesium dependence 
of kobs was analyzed using the Hill equation (Equation 4) (27) : 
[P]= [P]!(1" e"kobst )
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Equation 4  
where kobs is the cleavage rate constant measured at each magnesium 
concentration, kmax is the rate constant at saturating magnesium concentration, 
K1/2 is the magnesium concentration at ½ X kmax and nH is the Hill coefficient. 
Circular Dichroism measurement of (mt)pre-tRNATyr folding 
0.4 µM of (mt)pre-tRNATyr was heat denatured at 95oC for 3 min in water, 
incubated at 37oC for 10-15 min.and then buffer (30 mM MOPS, pH 7.6, 150 mM 
NaCl) was added and the mixture was incubated at 37oC for 30 min. The CD 
spectra of (mt)pre-tRNATyr was measured as a function of cobalt hexammine 
chloride (Cohex, Co(NH3)6Cl3) addition (0 to 0.25 mM) with a 2 min equilibration 
at 37oC after each addition. CD spectra were recorded using an AVIV 
spectropolarimeter and analyzed using Equation 4 to obtain the delta epsilon (Δε) 
at A264. Equation 5 was fit to the dependence of Δε on Cohex concentration to 
obtain the K1/2 for stabilization of (mt)pre-tRNATyr folding by Cohex. 
Equation 4  
Equation 5 
!! =
[Co(NH3)6Cl3]
K1/2 +[Co(NH3)6Cl3]  
where θ is the raw CD amplitude in mdeg, C is the concentration of the RNA, L is 
the cell path length in cm, and N is the number of nucleotides in RNA (30). 
kobs =
kmax[Mg2+ ]nH
K1/2nH +[Mg2+ ]nH
!! =
"
32980"C " L"N
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Results 
 
MRPP3 alone catalyzes the 5’ end maturation of (mt)pre-tRNA 
Since there is evidence that RNase P is a metal-dependent enzyme, we 
measured metal content of the protein using ICP-MS.  Using this method, we 
observed significant metal ion (Mg, Ni and Fe) contamination in MRPP3 with 
some metals co-eluting with the other two subunits of human mtRNase P protein 
after the first Ni(II)-IMAC column purification (Table 4-1). This metal 
contamination in the MRPP proteins could affect the catalytic activity of human 
mtRNase P. Therefore, as a final step in the purification, MRPP1, MRPP2 and 
MRPP3 proteins were dialyzed against 1 mM EDTA followed by a PD-10 gel 
filtration column to remove the EDTA. The ICP-MS results of proteins treated 
with EDTA indicate that purified MRPP1 contains 0.5 mol Mg/mol protein and 0.2 
mol Zn/mol protein while MRPP2 contains ≤ 0.02 mol metal/mol protein.  In 
contrast, ICP-MS data for two different preparations of MRPP3 indicates that one  
has a ~1:1 ratio of Zn:MRPP3 (0.9 mol Zn/mol MRPP3), while the second 
preparation has a 0.14:1 ratio of Zn:MRPP3 (0.14 mol Zn/mol MRPP3). The 
D478A/D479A MRPP3 mutant also has 0.18:1 ratio of Zn: MRPP3 (Table 4-1).  
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Table 4-1: Metal Content of purified MRPP1, MRPP2 and MRPP3a 
Protein Mg (µM) Fe (µM) Ni (µM) Zn (µM) 
After first 
nickel column 	   	   	   	  
MRPP1e 3.02 0.07	   0.115 0.598 
MRPP2e 1.39 0.04	   2.43 <0.02c  
 
MRPP3e 6.66 24.54	   6.05 1.30 
 
After 1mM 
EDTA dialysis 	   	   	   	  
MRPP1 0.5 0.07 <0.04b 0.2 
MRPP2 <0.4c 0.02 <0.04b <0.001 
MRPP3a <0.4 <0.02c 0.03 0.9 
MRPP3b 0.1 0.02 0.4 0.14 
D478A/479A 
MRPP3d 
0.4 <0.02c  0.3 0.18 
 
a The metal content of MRPP1, MRPP2 and MRPP3 proteins is represented as 
(mol of metal in protein – mol of metal in buffer)/mol protein. 
b Measured metal content is below the detection limit of the ICP-MS analysis. 
c Measured of metal content is lower than the metal content of the buffer (30 mM 
MOP (pH 7.8), 15% glycerol, 150 mM NaCl, 0.1 mM TCEP). The lower limit for 
Mg, Fe, Ni and Zn are < 0.4 µM, <0.02 µM, <0.04 µM, and <0.02 µM, 
respectively.   
d D435A/436A mutant of MRPP3 protein. 
e Measurement of metal content of MRPP1, MRPP2 and MRPP3 proteins after 
the first Ni(II)-IMAC column. 
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Previous analysis of the MRPP1/MRPP2/MRPP3 complex indicated that 
magnesium ions were important for the catalytic activity of mtRNase P (14,18).  
Therefore, to examine whether the purified MRPP3 protein could catalyze 
cleavage of the mitochondrial pre-tRNATyr, activity was assayed in the presence 
of 1 mM MgCl2 under single turnover condition where [E]/[S] ≥ 5-fold. The results 
indicates MRPP3 catalyzes complete cleavage of the 5’ end-labeled (mt)tRNATyr 
under these conditions to form a leader of 46 nucleotides, which is similar to the  
(mt)pre-tRNATyr cleavage by the MRPP1:MRPP2:MRPP3 complex (kobs = 0.14 ± 
0.01 min-1) (Figure 4-2 and Figure 4-9A) (14).  Furthermore, double aspartate 
residues mutation (D478/D479) which is proposed to coordinate catalytic metal 
ions in the MRPP3, decrease the MRPP3 catalytic activity significantly, with < 
20% (mt)pre-tRNATyr cleavage. The catalytic activity of PRORP1, a homolog of 
MRPP3, is also abolished when the same double aspartate residues are mutated 
to alanine in the PRORP1 (13). There results indicate that containing 0.9 mole 
Zn/mol protein has the highest activity with a kobs of 0.36 ± 0.01 min-1. 
Decreasing the bound zinc by 6-fold (0.14 Zn/MRPP3) is also decrease in the 
value of kobs to 0.01 ± 0.002 min-1 (Figure 4-3). These activity data indicate that 
MRPP3 alone catalyzes cleavage of (mt)pre-tRNATyr in the presence of Mg2+ ions 
and, furthermore, suggest that a bound zinc ion is also important for catalytic 
activity. 
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 Figure 4-2: Measurement of cleavage of (mt)pre-tRNATyr catalyzed by MRPP3, 
MRPP1:MRPP2:MRPP3 complex and D478/D479 MRPP3 mutant. 32P-labeled 
(mt)pre-tRNATyr (~0.01 nM) was incubated at 37oC for up to 4 hr with: (A) buffer 
only (30 mM MOPS, pH 7.6, 150 mM NaCl and 1 mM MgCl2); (B)  buffer plus 100 
nM D345/346 MRPP3 mutant; (C)  buffer plus MRPP3 (0.9 mole/ mol MRPP3); 
and (D) buffer plus MRPP1:MRPP2:MRPP3 complex in 2:4:1 ratio; The reaction 
was quenched with 50 mM EDTA and the reaction products were separated by 
PAGE gel and analyzed using a phosphorimager.  
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Figure 4-3: Single turnover measurement of (mt)pre-tRNATyr cleavage catalyzed 
by MRPP3 and MRPP3 double D435A/D436A mutant. 32P-labeled (mt)pre-
tRNATyr (~0.01 nM) was incubated with 100 nM of 0.9 Zn/MRPP3, 0.14 
Zn/MRPP3 or D435A/D436A MRPP3 ([E]/[S] ≥ 5-fold) in 30 mM MOPS, pH 7.6, 
150 mM NaCl and 1 mM MgCl2 at 37oC. The samples were fractionated on a 
PAGE and the fraction of pre-tRNA cleaved by MRPP3 as a function of time was 
quantified by PhosphorImager analysis. Equation 1 was fit to the data to 
calculate the observed cleavage rate constants, kobs for (mt)pre-tRNATyr 
catalyzed by: 0.9 mol Zn/mol MRPP3 () as 0.36 ± 0.01 min-1; 0.14 mol Zn/mol 
MRPP3 () as 0.01 ± 0.002 min-1; and D478A/D479A MRPP3 () as 0.005 ± 
0.001 min-1. 
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Metal-dependence of MRPP3 catalytic activity 
    The previous data demonstrate that the catalytic subunit of human mtRNase P 
(MRPP3) has catalytic activity in 1 mM Mg2+.  However, it is not clear whether 
this is either the optimal metal cofactor or concentration.  Analysis of metals 
(using ICP-MS) that co-elute with MRPP3 from the first Ni(II)-IMAC column 
indicate a high amount of magnesium, iron and zinc (Table 4-1).  These data 
suggest that MRPP3 could bind and/or be activated by iron, zinc or magnesium.  
The traditional method for measuring the identity of functional metal ions is to 
prepare enzyme with out metal ions and measure activity as metal ions are 
added back.  However, for MRPP3 this experiment is complicated by the metal-
dependent folding of the substrate, (mt)tRNATyr (31). Therefore, to investigate the 
role of inner sphere metal ions in activation of MRPP3 catalysis, metal titration 
was carried out in the presence of cobalt hexammine chloride (Cohex).  Cohex is 
an outer sphere metal ion that mimics magnesium hexahydrate and stabilizes the 
tertiary structure of RNA (27,32).  To examine whether Cohex stabilizes the 
tertiary structure of (mt)pre-tRNATyr, the circular dichroism spectra of (mt)pre-
tRNATyr was measured as a function of Cohex concentration (Figure 4-4A).  
These data demonstrate that the spectra of (mt)pre-tRNATyr in 250 µM Cohex is 
comparable to that measured in 1 mM MgCl2 (Figure 4-4C). Furthermore, these 
data can be reasonably described by a single binding isotherm with an apparent 
K1/2 of 54 ± 1 µM (Figure 4-4B). Therefore, low concentrations of Cohex are 
sufficient to stabilize the tertiary structure of (mt)pre-tRNATyr. 
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Experiments to measure the metal dependence of MRPP3 were carried out in 
the presence of 100 µM or 250 µM Cohex to fold  (mt)pre-tRNATyr and the 
cleavage reaction was initiated by adding MRPP3 (containing 0.9 mol Zn/mol 
protein). In the presence of 250 µM Cohex alone, cleavage of the 5’ end of 
(mt)pre-tRNA is not observed (Figure 4-5A), suggesting that a divalent cation that 
can form an inner sphere complex is essential for catalytic activity. Furthermore, 
< 40% and < 20% cleavage of (mt)pre-tRNA is observed in the presence of 
MRPP3 and either 100 nM ZnCl2 or FeCl2 (Figure 4-5C and 4-5D). The Fe 
experiments were done under anaerobic conditions to maintain the Fe(II) in the 
assay. Activation of cleavage was also not observed upon varying the 
concentration of ZnCl2 (25 nM to 300 nM) or FeCl2 (200 nM to 1 µM) (Figure 4-6).  
In the presence of 1 mM MgCl2, cleavage of the 5’ end of (mt)pre-tRNA catalyzed 
by MRPP3 is complete within one hour, with an observed pseudo first order rate 
constant of kmax of 0.14 ± 0.02 min-1. These data indicate that MgCl2 likely 
functions as a catalytic metal ion to activate MRPP3 (Figure 4-5B). Additionally, 
the observed rate constant, kobs, for the 5’ cleavage of (mt)pre-tRNA by MRPP3 
has a hyperbolic dependence (nH =1.2 ± 0.4) on the MgCl2 concentration with a 
kmax of 0.16 ± 0.02 min-1 and a K1/2Mg of 0.3 ± 0.1 mM (Figure 4-7).  
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Figure 4-4: (mt)pre-tRNATyr folding measurement in the presence of Cohex by 
performing CD analysis. (A) Representative of CD spectra for (mt)pre-tRNATyr 
folding in the presence of 0.01 mM, 0.025 mM and 0.15 mM Cohex at 37oC. (B) 
Measurement of 0.4 µM (mt)pre-tRNATyr folding in 30 mM MOPS, pH 7.6, 50 mM 
NaCl and various Cohex concentration ( 0 to 0.15 mM Cohex). The CD spectra 
were analyzed using Eq. 4 to obtain the delta epsilon at A264. The delta epsilon at 
A264 was plotted as a function of Cohex concentration and fitted using Eq. 5.  The 
K1/2Cohex for (mt)pre-tRNATyr folding is ~ 54 ± 1 µM. (C) Representative of CD 
spectra of 0.4 µM (mt)pre-tRNATyr folding in the presence of 0.25 mM Cohex () 
and 1 mM MgCl2 (). 
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Figure 4-5: Metal-dependence of pre-tRNA cleavage catalyzed by MRPP3. The 
32P-labeled (mt)pre-tRNATyr (~0.01 nM) was incubated with 100 nM MRPP3 in 30 
mM MOPS, pH 7.6, 150 mM NaCl, 250 µM cohex at 37oC for up to one hour in 
the presence of various metal ions, including: (A) 250 µM Cohex only; (B) 1 mM 
MgCl2; (C) 100 nM ZnCl2 and (D) 100 nM FeCl2. The (mt)pre-tRNATyr cleavage 
was performed under anaerobic conditions.  
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Figure 4-6: Measurement of cleavage of (mt)pre-tRNATyr catalyzed by MRPP3 in 
the presence of ZnCl2 and FeCl2. 32P-labeled (mt)pre-tRNATyr (~0.01 nM) was 
incubated at 37oC for up to 1 hr with 0.9 mol Zn/mol MRPP3 in 30 mM MOPS, pH 
7.6, 150 mM NaCl, 250 µM cohex and (A) 25 nM ZnCl2, (B) 37.5 nM ZnCl2, (C) 
50 nM ZnCl2, (D) 200 nM ZnCl2, (E) 300 nM ZnCl2, (F) 200 nM FeCl2, (G) 500 nM 
FeCl2, and (H) 1 µM FeCl2. The reaction was quenched with 50 mM EDTA and 
the reaction products were separated by PAGE and analyzed using a 
phosphorimager. 
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Figure 4-7: Measurement of the magnesium dependence of the observed 
cleavage rate, kobs catalyzed by MRPP3 for (mt)pre-tRNATyr. (A) Cleavage of 32P-
labeled (mt)pre-tRNATyr (~0.01 nM) was catalyzed by 100 nM MRPP3 in 30 mM 
MOPS, pH 7.6, 250 µM Cohex, 150 mM NaCl, and varied MgCl2 concentration 
(0.15 mM to 3 mM MgCl2) at 37oC. The fraction of (mt)pre-tRNATyr was 
determined as described in the legend of Figure 4.3.  Eq.1 was fit to the time-
dependence of cleavage yielding the following values for kobs: 0.15 mM MgCl2 (), 
0.047 ± 0.005 min-1; 0.25 mM MgCl2 (), 0.063 ± 0.003 min-1; 0.5 mM MgCl2 (), 
0.083 ± 0.004 min-1 ; 3 mM MgCl2 (), 0.14 ± 0.02 min-1 ; 1 mM MgCl2 (), 0.14 
± 0.01 min-1. (B) Magnesium ion dependence of kobs for cleavage of (mt)pre-
tRNATyr by MRPP3. The kobs demonstrated a hyperbolic dependence on the 
magnesium ion concentration; a fit of Eq. 3 to these data yielded values for kmax 
of 0.16 ± 0.02 min-1, K1/2,Mg of 0.3 ± 0.1 mM and nH  of 1.2 ± 0.4. 
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Mutations in putative Mg2+ binding site 
A comparison of conserved sequences in MRPP3 and a recently identified 
homolog from chloroplasts, known as PRORP1, (13) demonstrate a series of 
conserved aspartate and histidine residues at the C-terminus of these proteins 
that have been proposed to be important for metal coordination (14,33) (Fig. 4-1).   
These proteins also have weak homology to a PIN domain where a crystal 
structure indicates that the aspartate residues coordinate a magnesium ion.  In 
Arabidopsis thaliana RNase P (PRORP1) catalytic activity is abolished when two 
of these adjacent aspartates (D474, D475) are mutated to alanine.  To examine 
whether the homologous aspartate residues in MRPP3 are important for 
coordinating the catalytic metal ions in the human mtRNase P complex, the 
D478A/D479A MRPP3 mutant was prepared.  This protein co-purifies with 
substoichiometric concentrations of Zn (0.18 mol/mol protein) and Ni (0.4 µM) 
(Table 4-1). Furthermore the activity in the presence of 1 mM MgCl2 is decreased 
significantly compared to the wild-type Zn-bound MRPP3 with a single turnover 
kobs of 0.005 ± 0.001 min-1 (Figure 4-3). 
Zinc ions enhance the cleavage rate of the (mt)pre-tRNA by MRPP3 
The data in Figure 4.3 indicate that MRPP3 with nearly stoichiometric bound zinc 
(0.9 mol Zn/mol protein) has a significantly higher cleavage rate constant (kobs = 
0.36 ± 0.01 min-1) than MRPP3 containing 0.14 mol Zn/mol protein (kobs = 0.01 ± 
0.002 min-1) suggesting that a bound zinc cofactor may be important for catalytic 
activity in addition to Mg2+. To further evaluate the differential activity of these two 
enzyme preparations, the dependence of the observed rate constants, kobs on the 
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concentration of 0.9 mol Zn/mol MRPP3 and 0.14 mol Zn/mol MRPP3 (0 to 300 
nM) was measured in the presence of 1 mM MgCl2. For Zn-bound MRPP3, the 
single turnover rate constant, kobs,, has a nearly linear or slightly hyperbolic 
dependence on the enzyme concentration (Fig. 4-8C).  A fit of a Eq. 2 to the data 
yields values for kmax, K1/2 and kmax/K1/2 of 3.0 ± 0.8 min-1, 790 ± 300 nM and 
0.004 ± 0.002 min-1nM-1 = 2 x 106 M-1min-1 = 3.3 x 104 M-1s-1. A linear fit of the 
data yields a comparable value for kmax/K1/2 (0.003 ± 0.0001 min-1nM-1). The 
activity of MRPP3 containing limited bound zinc 0.14 mol Zn/mol MRPP3 is 
significantly decreased.  A linear fit of the dependence of kobs on the MRPP3 
concentration yields a value for kmax/K1/2 of 5 ± 0.7 × 10-5 min-1nM-1 = 5 x 104 M-
1min-1, which is 40-fold lower than the activity of MRPP3 with stoichiometric zinc 
(Figure 4-8C). The reduction of 0.9 mol Zn/mol MRPP3 activity relative to 0.14 
mol Zn/ mol MRPP3 activity does not seem to correlate with the reduction of zinc 
content (~7-fold).  This could be due to the 0.14 zinc could be nonspecifically 
bound to the MRPP3. These enhanced activity of the zinc-bound MRPP3 
demonstrates a bound zinc ion is important for the catalytic activity.  Furthermore, 
these data suggest that the affinity of MRPP3 for pre-tRNA under these 
conditions is nearly 1 µM, assuming that the value of K1/2 approximates the pre-
tRNA binding affinity (i.e. k-1 > kmax, Scheme 1).  This affinity is significantly 
weaker than the affinity of bacterial RNase P for pre-tRNA, which is in the 10 nM 
range (11,34). 
Function of other proposed subunits in pre-tRNA cleavage activity  
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Preceding studies have indicated that three subunits (MRPP1, MRPP2 and 
MRPP3) are essential for catalysis of 5’ end cleavage of (mt)pre-tRNA for the 
mitochondrial RNase P.  Our studies indicates that MRPP3 alone is sufficient to 
catalyze the 5’ end of the (mt)pre-tRNA (Figure 4-1), similar to the results 
obtained for the chloroplast RNase P where PRORP1, the protein homologous to 
MRPP3 catalyzes pre-tRNA cleavage (13). To examine the role of MRPP1 and 
MRPP2 in catalysis of pre-tRNA cleavage, the kobs for cleavage of (mt)pre-tRNA  
catalyzed by a 2:4:1 ratio of MRPP1:MRPP2:MRPP3 (the proposed RNase P 
complex (14)) as compared to cleavage in the presence of MRPP3 alone in the 
presence of 1 mM MgCl2 (Figure 4-1). The data demonstrate that the single 
turnover rate constant for pre-tRNA cleavage catalyzed by the 
MRPP1/MRPP2/MRPP3 complex (0.14 ± 0.01 min-1) is more than 2-fold slower 
than cleavage by MRPP3 (0.36 ± 0.01 min-1) indicating that the MRPP1/MRPP2 
complex does NOT enhance the cleavage rate of MRPP3 complex. Furthermore, 
similar results are obtained from a comparison of the magnesium dependence of 
the kobs of the (mt)pre-tRNATyr cleavage catalyzed by the 
MRPP1/MRPP2/MRPP3 complex and MRPP3 alone; under these conditions 
both enzymes are maximally activated by 0.25 mM MgCl2 with kobs values of 0.15 
± 0.003 min-1 and 0.4 ± 0.002 min-1 for the MRPP1/MRPP2/MRPP3 complex and 
MRPP3 alone, respectively (Figure 4-9). These results demonstrate that 
observed cleavage rate of MRPP3 is >2-fold faster than the 
MRPP1/MRPP2/MRPP3 complex.  These data indicate that the MRPP3 subunit 
is sufficient to catalyze the cleavage reaction.  
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Figure 4-8: Catalysis of cleavage of (mt)pre-tRNATyr by Zn-MRPP3 under single 
turnover conditions.  (A) The cleavage of 32P-labeled (mt)pre-tRNATyr (~0.01 nM) 
catalyzed by varied concentrations of MRPP3 (0.9 mol zinc/mol MRPP3) in 30 
mM MOPS, pH 7.6, 150 mM NaCl, and 1 mM MgCl2 at 37oC. The fraction 
cleaved is measured as described in the legend of Fig. 4.3.  Eq. 1 is fit to the 
time-dependence of cleavage of (mt)pre-tRNATyr yielding the following values of 
kobs: 50 nM MRPP3 (), 0.11 ± 0.009 min-1; 100 nM MRPP3 (), 0.36 ± 0.01 min-
1; 150 nM MRPP3 (), 0.054 ± 0.04 min-1 ; 200 nM MRPP3 (), 0.61 ± 0.04 min-1 
and 300 nM MRPP3 (), 0.79 ± 0.04 min-1. (B) The cleavage of 32P-labeled 
(mt)pre-tRNATyr (~0.01 nM) catalyzed by varied concentrations of MRPP3 (0.14  
mol zinc/mol MRPP3) in 30 mM MOPS, pH 7.6, 150 mM NaCl, and 1 mM MgCl2 
at 37oC. The measured values for kobs are: 50 nM MRPP3 (), 0.0053 ± 0.0006 
min-1; 70 nM MRPP3 (), 0.0063 ± 0.0001 min-1; 100 nM MRPP3 (), 0.0079 ± 
0.0003 min-1 ; 150 nM MRPP3 (), 0.009 ± 0.0003 min-1 ; 200 nM MRPP3 (), 
0.01 ± 0.0004 min-1 and 275 nM MRPP3 (), 0.01 ± 0.0004 min-1.  (C) The 
dependence of the observed rate constant, kobs, for catalysis of (mt)pre-tRNATyr 
cleavage on the MRPP3 concentration. The values for kmax and K1/2  of 0.9 
Zn/MRPP3 () are 3.0 ± 0.8 min-1 and 790 ±  300 nM respectively, when Eq 2 Is 
fit to the data. The values for kmax/K1/2 of 0.003 ± 0.0001 min-1nM-1 (0.9 
Zn/MRPP3 ()) and 5 ± 0.7 ×10-5 min-1nM-1 (0.14 Zn/MRPP3 ()) are obtained 
from a fit of Eq. 3 to the data.  
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Figure 4-9: (A) Cleavage of (mt)pre-tRNATyr catalyzed by MRPP3 and 
MRPP1:MRPP2:MRPP3 complex in 2:4:1 ratio under single turnover conditions.  
32P-labeled (mt)pre-tRNATyr (~0.01 nM) was incubated with 100 nM of MRPP3 
(0.9 mol Zn/mol protein) and 200:400:100 nM of MRPP1:MRPP2:MRPP3 ([E]/[S] 
≥ 5-fold) in 30 mM MOPS, pH 7.6, 150 mM NaCl and 1 mM MgCl2 at 37oC. Eq. 1 
was fit to the time-dependence of the fraction of pre-tRNA cleaved catalyzed by 
MRPP3 or MRPP1:MRPP2:MRPP3 complex. The kobs for (mt)pre-tRNATyr 
catalyzed by MRPP3 () is 0.36 ± 0.01 min-1 and by the MRPP1:MRPP2:MRPP3 
complex () is 0.14 ± 0.01 min-1. (B) Magnesium ion dependence of the single 
turnover rate constant for cleavage of (mt)pre-tRNATyr catalyzed by MRPP3 or 
MRPP1:MRPP2:MRPP3 complex. In the absence of Cohex, the kobs is not 
dependent on the magnesium concentration (0.25  - 2.5 mM magnesium).  The 
values of kobs  are 0.4 ± 0.06 min-1 for MRPP3 () and 0.13 ± 0.03 min-1 for the 
MRPP1:MRPP2:MRPP3 complex (). 
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Discussion 
 
Subunit structure of mtRNase P 
The recently discovered human mtRNase P contains one or more protein 
subunits but does not contain a catalytic RNA subunit, as observed for the well-
studied ribonuclear complex RNase P from bacteria, archea and eukaryotes 
(14,18,35). Rossmanith and coworkers suggest that the three MRPP1, MRPP2 
and MRPP3 subunits are essential for human mtRNase P catalysis (14). 
However, the role of each of these protein subunits in the human mtRNase P is 
still unclear. During purification of MRPP1 using Ni(II)-IMAC resin, MRPP2 co-
eluted with MRPP1, suggesting that these two proteins form a complex. Both the 
MRPP1 and MRPP2 have putative RNA-binding domains known as Rossmann-
fold and are proposed to play a role in substrate recognition.  Bioinformatic 
domain analysis of MRPP3 identifies two PPR motifs, which have been 
suggested to be important for RNA binding. The PPR motif is a 35 amino acids 
tandem repeat protein and has 2 to 26 tandem arrays. The PPR have been 
involved in post transcriptional modification process, including editing events, 
RNA splicing and maturation and RNA stabilization (36). The gel mobility shift 
assays indicate that chloroplast PPR proteins such as PPR5 and CRP1 bind to 
the single stranded 31-mer RNA and unspliced trnG-UCC, a pre-tRNA that 
associate with group II intron, respectively (37). Furthermore, 9 to 6 nucleotides 
deletion from the 5’ and 3’ end of the unspliced trnG-UCC decrease the affinity 
for PPR5, suggesting that PPR proteins have a RNA binding domain.  The PPR 
motifs are related to TPR motif that form antiparallel α-helices and a superhelix if 
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> two tandem arrays presence. Therefore, structure prediction of the PPR motif 
suggested that PPR motif has similar tertiary structure as the TPR motif (36). 
Additionally, sequence homology identifies several conserved aspartate and 
histidine residues that are proposed to form a novel metallonuclease family (see 
Figure 4-1).   
Two years after identification of human mtRNase P, a second proteinaceous 
RNase P from Arabidopsis thaliana is unearthed, known as PRORP1 (13). 
PRORP1 is a single protein subunit that is localized to mitochondrial and 
chloroplast in plants and is sufficient to catalyze cleavage of the 5’ end of the pre-
tRNA.  Based on sequence homology, PRORP1 is ortholog to the MRPP3 
subunit that is also composed of two PPR motifs and conserved aspartates and 
histidine residues at the C-terminus (Figure 4-1).  The discovery of PRORP1 
catalysis of pre-tRNA cleavage led to the question as to whether all three 
subunits are essential for the catalytic activity of the mitochondrial enzyme. In our 
experiments, under single turnover condition, MRPP3 alone catalyzes cleavage 
of the 5’ end of the (mt)pre-tRNATyr to completion within an hour, which is similar 
to the (mt)pre-tRNATyr cleavage by the MRPP1:MRPP2:MRPP3 complex, 
forming a 46 nucleotides leader (Figure 4-2). In addition, double mutation of the 
two conserved aspartate residues to alanine (D478A/D479A) in the MRPP3, 
which proposed to coordinate the catalytic metal ions, significantly decrease the 
MRPP3 catalytic activity (Figure 4-3). Furthermore, PRORP1 catalytic activity is 
also abolished when the same double aspartate residues were mutated to 
alanine (D474A/D475A) (13). These data demonstrate that MRPP3 alone is 
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sufficient to catalyze (mt)pre-tRNA cleavage, as previously observed for 
PRORP1. 
Additionally we evaluated whether the other two subunits proposed to be 
essential for the catalytic activity of mtRNase P enhanced the catalytic activity.  
Contrary to our expectations, addition of the MRPP1/MRPP2 subunit to MRPP3 
decreased the single turnover rate constant for cleavage of (mt)pre-tRNATyr 
cleavage by 2 – 3-fold under a variety of conditions. These data indicate that 
addition of the MRPP1/MRPP2 complex to MRPP3 does NOT enhance the 
catalytic activity of the human mtRNase P at saturating magnesium ions.  The 
lack of enhancement of activity under the single turnover conditions with sub-
saturating enzyme also indicates that MRPP1/MRPP2 does not increase pre-
tRNA affinity. Therefore, our data suggest that the human mitochondrial RNase P, 
like the Arabidopsis chloroplast enzyme, requires a single subunit, MRPP3, for 
catalytic activity.  At this point, a role for MRPP1 and MRPP2 in catalysis of pre-
tRNA cleavage is unclear. Previous studies suggested that all three MRPP 
proteins components are required for (mt)pre-tRNA cleavage, however, in our 
single turnover condition, the MRPP3 is sufficient to catalyze the (mt)pre-tRNA 
cleavage. The discrepancy between these two results could be due to several 
factors, such as contaminating metal ions that could potentially inhibit the 
catalytic activity of MRPP3, lack of zinc metal ions, which is important in 
enhancing the MRPP3 catalytic activity or nucleic acids contamination in the 
MRPP3 proteins. Alternatively, it is possible that 2:4:1 ratio of 
MRPP1:MRPP2:MRPP3 protein is not optimal for mtRNase P catalytic activity 
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and the ratio of MRPP1:MRPP2:MRPP3 protein need to be optimized or MRPP1 
and MRPP2 require cofactors such as SAM and NAD+ to enhance the mtRNase 
P catalytic activity. Therefore, the vitality of MRPP1 and MRPP2 in human 
mtRNase P catalysis need to be carefully examined in the future. 
Zinc Dependence of MRPP3 
Divalent metal ions play an essential role in metalloprotein catalysis, where they 
can be either catalytic and/or structural functions.  All known ribozyme RNase P 
require Mg2+ ions for RNase P catalysis, in vivo (26,32).  In other enzymes, 
conserved aspartate and histidine residues have been shown to coordinate metal 
ions, such as magnesium, zinc, and iron to form a metal active site of the 
metalloproteins (33,38).  To identify whether MRPP3 contains any high affinity 
metal binding sites, bound metal ions were measured using ICP-MS.  After 
fractionation using Ni(II)-IMAC, a number of metal ions (Mg, Fe, Ni and Zn) co-
elute with MRPP3 (Table 4-1). To remove contaminating metal ions, MRPP3 was 
dialyzed against EDTA followed dialysis against metal free buffer.  This 
procedure successfully removed all of the contaminating Fe, Mg and Ni; however, 
fortuitously, the amount of bound zinc resulting from this procedure varied from 
0.1 mol Zn/ mol MRPP3 to 0.9 mol Zn/ mol MRPP3. When 0.15 mg of MRPP3 is 
dialyzed in 1L EDTA buffer, the Zn content of MRPP3 is  ~ 0.1 mol, while 
dialyzing  ~ 1.5 mg of MRPP3 in the 1L EDTA buffer, MRPP3 has stoichiometric 
bound zinc to the protein. Therefore, the amount of bound zinc to MRPP3 could 
be varied when the dialyzing different MRPP3 concentration in 1L EDTA buffer. 
Furthermore, the single turnover rate constant measured under standard 
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conditions (1 mM MgCl2) varies with the zinc content of the enzyme; MRPP3 with 
nearly stoichiometric bound zinc (0.9 mol Zn/ mol MRPP3) catalyzes cleavage of 
(mt)pre-tRNATyr 36-fold faster than MRPP3 containing 0.14 mol Zn/ mol MRPP3.  
This is more activation that would be expected from the 6-fold increase in zinc 
content, suggesting that that the 0.14 mol zinc may not be bound to the correct 
site, perhaps due to structural alterations of the enzyme. Consistent with this, 
incubation of the apo-enzyme with zinc was not able to reactivate the enzyme.  
Frequently it is difficult to reconstituted cysteine-containing zinc sites due to 
cysteine oxidation in the apo-enzyme. This is the first evidence that the catalytic 
component of mtRNase P, MRPP3, requires a tightly bound zinc for function that 
serves either a catalytic and/or structural role. 
MRPP3 is Activated by Magnesium 
Evaluation of the role of additional divalent cations in activating MRPP3 is 
complicated by the requirement of divalent cations to stabilize the folded 
structure of pre-tRNA.  To circumvent this difficulty, we used the outer sphere 
magnesium mimic, cobalt hexammine to stabilize the pre-tRNA structure.  Under 
these conditions, the zinc-bound enzyme does not catalyze cleavage of the 5’ 
end of (mt)pre-tRNATyr cleavage in the presence of cohex alone, cohex with Zn2+ 
ions or cohex with Fe2+ ions (Figure 4-5A, 5C, 5D). However, in the presence of 
cohex with Mg2+ ions, MRPP3 catalyzes complete cleavage of the 5’ end of 
(mt)pre-tRNATyr (Figure 4-5B). These data demonstrate that in addition to the 
tightly bound zinc ion, Mg2+ ions activate the catalytic activity of MRPP3, and this 
requirement for Mg2+ cannot be fulfilled by Zn2+ or Fe2+ ions. In the presence of 
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cohex, the kobs for (mt)pre-tRNA cleavage is dependent on the Mg2+ ion 
concentration, with a kmax of 0.16 ± 0.02 min-1, K1/2,Mg of 0.3 ± 0.1 mM and a hill 
constant, nH = 1.2 ± 0.4, indicating that MRPP3 has a minimum of one 
magnesium binding site with an apparent affinity of ~ 300 µM (Figure 4-6B).  In 
the absence of cohex, the activity is independent of Mg2+ concentration above 
250 µM suggesting that the Mg2+ affinity is enhanced.  These data suggest that 
cohex competes with the magnesium binding site, as previously observed in for 
other enzymes (27). The estimate for readily exchangeable Mg(II) in mammalian 
cells is ~ 1 mM (39-41), which is sufficient to activate MRPP3 activity in vivo. 
Together these results demonstrate that MRPP3 requires both magnesium and 
zinc cofactors to activate the catalytic activity.  Both magnesium and zinc can 
function to stabilize the catalytic transition state or magnesium could play a 
catalytic role while the zinc plays a role in stabilizing the MRPP3 structure.  
Metal Ion Binding Sites in MRPP3 
PFAM analysis of MRPP3 indicates a PPR motif followed by a zinc-binding motif 
and a nuclease metal binding domain.  This putative zinc binding site could 
explain the catalytic requirement for bound zinc in MRPP3 (Figure 4-1). The 
proposed zinc-binding domain of the MRPP3 has three cysteine residues that are 
generally observed in a structural zinc site (33,42). Sequence alignments of 
MRPP3 homology indicate that two of these three cysteine residues are highly 
conserved (C348 and C351), while non-conserved cysteine are located at C367 
of the MRPP3. However, sequence alignments of MRPP3 homologs also shown 
a highly conserved cysteine and histidine at C578 and H504 of the MRPP3. 
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Therefore, the structure zinc site of the MRPP3 could form by either four cysteine 
or three cysteine and a histidine residues to coordinate the zinc ligand (33,38).  
    The PFAM analysis predicted that the MRPP3 has a NYN domain, a nuclease 
metal domain that has four conserved aspartate residues (D409, D478, D479 
and D499) (15). The NYN domain is proposed to have similar protein fold as the 
PIN and FLAP/5’  3’ exonuclease superfamilies and both have four conserved 
aspartate residues that are proposed to coordinate Mg2+ ions (5). Crystal 
structure of the a PIN domain of human SMG6, a nonsense-mediated mRNA 
decay (NMD) proteins, indicate three conserved aspartate residues, including 
D1251, D1353 and D1392 that could coordinate Mg2+ ion (corresponding to D409, 
D478 and D499 in the MRPP3) (43,44). Superimpose of the magnesium binding 
site of T4 RNase H, a FLAP nuclease family, to the SMG6 structure, suggest that 
D1251, D1353 and D1392 can form similar magnesium binding site as the T4 
RNase H (44). Hence, the conserved aspartate residues (D409, D478 and D499) 
can form a magnesium binding site of the MRPP3.  Furthermore, double 
mutation at D478 and D479 residues to alanine in the MRPP3 drastically 
decrease the MRPP3 catalytic activity, suggesting that the mutation of these 
aspartate residues affect the binding of the magnesium in the magnesium 
binding site (Figure 4-3).   Therefore, we speculate that MRPP3 has at least one 
magnesium binding site that coordinates a catalytic Mg2+ ion as well as a zinc 
binding site that could be important for structural stabilization of MRPP3 or 
substrate binding.  
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In summary, the metal requirement of MRPP3 in human mtRNase P catalysis is 
explored. Investigation of the function of metal ions in human mtRNase P 
catalysis has demonstrated that MRPP3 is catalytically active alone in vitro, and 
therefore is the catalytic subunit (and likely the only essential subunit) of the 
human mtRNase P. Addition of MRPP1 and MRPP2 subunits to MRPP3 subunit 
moderately decrease the catalytic activity of the human mtRNase P.  
Furthermore, we have discovered a requirement for two metal ions, including at 
least one Mg2+ ion that activates catalysis and a tightly bound zinc ion that could 
serve to stabilize the structure of MRPP3 to activate catalysis. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
The objective of this research is to elucidate the substrate recognition of the pre-
tRNA by bacterial RNase P and to investigate the catalytic mechanism of the 
human mtRNase P complex, including identifying important metal ions. These 
studies established that in bacterial RNase P, P RNA, P protein and metal ions 
function collectively to contribute to pre-tRNAs recognition. Additionally, the work 
presented in this thesis provides the first direct evidence of that MRPP3 is the 
catalytic subunit of mtRNase P and that catalytic activity requires both a high 
affinity bound zinc ion and a weaker bound Mg2+ ions.  
 
Recognition of the N(-2) and N(-3) nucleotides in the leader of pre-tRNA by 
bacterial RNase P 
     Bacterial RNase P recognizes the tertiary structure of pre-tRNA (1-5) and 
makes sequence-specific contacts with the 3’ CCA. Bioinformatics analysis of 
161 bacterial pre-tRNA genes also suggest a sequence preference in the 5’ 
leader, with stronger sequence preferences near the cleavage site (6,7). In this 
work, binding affinity studies of B. subtilis RNase P with B. subtilis pre-tRNAAsp 
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illustrate a sequence preference for adenosine and purine at N(-2) and N(-3) 
nucleotides of the 5’ leader by 10-fold and 6.5-fold, respectively. Sequence 
specific interactions between the non-conserved nucleotide, G319 at J18/2 of the 
P RNA, and the N(-2) nucleotide contribute to the sequence preference at this 
position. Compensatory mutation data suggest that the G319 forms a trans 
Watson-Crick-sugar-edge interaction with the base at N(-2) position of pre-tRNA. 
Additionally, binding affinity data indicate that the N61, R62, and R65 residues at 
the “RNR” motif of the P protein indirectly affect the N(-3) sequence selectivity.  
  Pre-tRNA binding to RNase P is a two step mechanism, where the initial 
collision of E and S forms an E.S complex followed by a conformation change 
that is stabilized by the addition of divalent metal ions, such as Mg2+ and Ca2+ 
ions (8). The N(-2) sequence selectivity is not Ca2+-dependence, indicating that 
the interaction with the N(-2) base occurs at the initial E.S complex.  However, 
the N(-3) sequence selectivity is dependent on the Ca2+ concentration, 
suggesting that the N(-3) sequence selectivity is coupled to the metal-stabilized 
conformational change of the E.S complex. The biochemical studies presented in 
chapter 2 demonstrate that both the sequence specificity of RNase P for the pre-
tRNA leader and the metal-stabilized conformational change of the RNase P.pre-
tRNA complex contribute to the RNase P substrate recognition. 
 
Expression and purification of MRPP1, MRPP2 and MRPP3 in E. coli  
Recombinant expression of MRPP1, MRPP2 and MRPP3 are performed using 
BL21(DE3)pLysS and Rosetta(DE3) cells in E. coli. Expression of these 
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recombinant proteins is induced by addition of high IPTG (1 mM IPTG) at low 
temperature (≤ 16oC) to increase the protein yield and reduce proteolysis (8,9). 
The 6xHis-tagged recombinant proteins are purified using Ni(II)-IMAC column 
chromatography to ≥ 70% purity. The His-tags are cleaved from MRPP1, MRPP2 
and MRPP3 using 3C or TEV protease with ≥ 50% efficiency, respectively. The 
cleaved proteins are further purified using a second Ni(II)-IMAC column. For 
MRPP3, a final DEAE column is used to remove contaminating nucleic acids. 
Metal ion contamination was observed in the protein samples after the first Ni(II)-
IMAC purification. These metal ions can be eradicated from the recombinant 
proteins using chelating agents, such as EDTA, by overnight dialysis at 4oC. The 
work presented in chapter 3 demonstrates that MRPP1, MRPP2, and MRPP3 
are successfully expressed in E. coli cells and purified using affinity and anion-
exchange chromatography. 
 
MRPP3, the catalytic component of human mtRNase P 
Previous experiments indicated that three subunits, MRPP1, MRPP2 and 
MRPP3, are required for catalyzing the 5’ end maturation of human (mt)pre-
tRNATyr. In the published work, about 20% of (mt)pre-tRNATyr is cleaved by the 
human mtRNase P at 5 min under single turnover conditions (10). Sequence 
conservation and PFAM analysis indicates that MRPP3 contains two PPR motifs, 
a zinc binding domain, and four highly conserved amino acids (3 aspartates and 
1 histidine) that could be important for RNA binding and/or coordinating catalytic 
or structural metal ions (11). These data suggested that MRPP3 could be a 
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member of a new family of metallonucleases. Furthermore, PRORP1 from 
Arabidopsis thaliana, a homolog of MRPP3, is a single protein that catalyzes 
cleavage of the Arabidopsis thaliana (mt)pre-tRNACys (12). In this work, we 
demonstrated that MRPP3 alone could also catalyze cleavage of (mt)pre-tRNATyr 
under single turnover conditions with a kobs of 0.36 ± 0.01 min-1 at 100 nM 
MRPP3 in the presence of 1 mM MgCl2. This observed rate constant is not 
enhanced by the addition of MRPP1 and MRPP2. These data clearly 
demonstrate that the MRPP3 is the catalytic component and, possibly, only 
required subunit of human mtRNase P.  
 
Identification of metal ions activating the MRPP3 catalysis 
All known RNA-containing RNase P enzymes require Mg2+ ions for catalysis, in 
vitro (13-18).  However, the metal dependence of the mtRNase P is unclear (10).  
ICP-MS analysis of MRPP3 after the initial Ni(II)-IMAC column indicated that high 
iron and zinc co-eluted with the enzyme. MRPP3 has three conserved aspartate 
and one conserved histidine residues located in the C-terminal domain, which 
have been proposed to coordinate catalytic metal ions (19,20). To evaluate the 
role of metal ions in activating MRPP3 compared to stabilizing the structure of 
the pre-tRNA substrate, the dependence of the catalytic activity of MRPP on 
divalent metal ions (Mg2+, Fe2+ and Zn2+) were measured in the presence of 
cohex. The pre-tRNA tertiary structure is stabilized by cohex (17). In the 
presence of cohex, MRPP3 catalytic activity is enhanced only by the addition of 
Mg2+ ions, but not Fe2+ and Zn2+ ions.  These data suggest that catalytic activity 
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of MRPP3 requires a metal that can form inner sphere coordination with 
selectivity for Mg2+.  The dependence of the activity of MRPP3 on the Mg2+ is 
hyperbolic with K1/2Mg of 300 ± 100 µM and nH of 1.2 ± 0.4. Additionally, a ~1:1 
ratio of Zn:MRPP3 enhances the catalytic activity of MRPP3 by 36-fold relative to 
the 0.14:1 ratio of Zn:MRPP3 suggesting that a tightly bound, stoichiometric zinc 
ion enhances catalytic activity. Addition of MRPP1 and MRPP2 to MRPP3 
decreases the kobs by 2- to 3-fold. The metal dependence studies presented in 
chapter 4 demonstrate that at least two types of metal ions are essential for 
MRPP3 activity. We speculate that Mg2+ ion is the catalytic metal ions, while a 
structural zinc may stabilize structure required for MRPP3 catalytic activity.  
 
Future Directions 
 
Determine the metal binding site of the MRPP3 
Metal-dependent protein nucleases generally possess ≥ 2 highly conserved 
acidic active site residues that bind metal ion(s) (20,21). These metal ions can 
have either a structural or catalytic function.  For example, the metal ion can  
activate catalysis by: coordinating the scissile phosphodiester, activating the 
nucleophile, stabilizing the transition state, and/or protonating the leaving group. 
Sequence alignments of MRPP3 homologs reveal eight conserved cysteine, 
aspartate, and histidine residues in the C-terminal domain that commonly 
coordinate Zn2+ (Asp, His, Cys) or Mg2+ (Asp) bound to proteins. The results in 
Chapter 4 demonstrate that MRPP3 contains at least one bound Mg2+ and one 
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bound zinc ion that are essential for efficient catalysis..  Pfam analysis of MRPP3 
indicates a zinc binding domain and a NYN domain, which are proposed to 
coordinate a structural zinc and a catalytic Mg2+, respectively (11,22). Pfam 
analysis indicates that the zinc binding domain of MRPP3 has three cysteine 
residues (Cys348, Cys351 and Cys367); however sequence alignments of 
MRPP3 indicate that only two of the three cysteines (Cys348 and Cys351) are 
conserved (Figure 4-1), suggesting that these two amino acids likely form 2 of 
the 3-4 ligands that coordinate a bound zinc ion; a conserved histidine in the 
NYN domain could be an additional ligand. Additionally, the three conserved 
aspartate residues could coordinate Mg2+ to activate catalysis.  The structure of 
NYN (also called PIN) domains in SMG5 and SMG6, cofactors in Nonsense-
mediated decay, visualize Mg2+ binding to 3 aspartate residues (23). Alanine 
substitution of ligands that coordinate catalytic and structural metal ions in 
metalloenzymes generally decrease the catalytic activity (>100-fold) significantly 
and/or increase the metal concentration required to activate catalysis (24). 
Therefore, we propose to: 
(1) Substitute alanine for the conserved aspartate and histidine residues in 
MRPP3 (D409, D478, D479 and H504) and measure the catalytic activity of 
MRPP3. The function of these residues in metal binding will be assessed by 
measuring the dependence of activity on both the magnesium and MRPP3 
concentrations as well as the analyzing the metal content bound to the 
mutant MRPP3 subunits using ICP-MS.  
(2) Identify the protein side chains that coordinate zinc in MRPP3. The three 
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cysteine residues in the zinc binding domain identified by pfam analysis (Cys 
348, 351 and 367) will be substituted with alanine and the dependence of the 
activity of MRPP3 on zinc concentration will be measured. The zinc content 
of the mutant MRPP3 will be determined by ICP-MS analysis. If these 
cysteine residues coordinate the zinc metal, alanine mutation will sequester 
the zinc from the MRPP3 and decreased the MRPP3 catalytic activity.  
Mutations in other conserved His, Cys and Asp will be prepared and 
analyzed to identify additional zinc ligands. 
 
Determine the roles of MRPP1 and MRPP2 in human mtRNase P catalysis 
    Single turnover measurement of the catalytic activity of the 
MRPP1/MRPP2/MRPP3 complex compared to MRPP3 alone indicates that the 
two additional subunits moderately decreases the observed cleavage activity. 
The reasons for this result are not clear.  It is possible that MRPP1 and MRPP2 
are not essential components on of human mtRNase P.  However, this result 
could be explained by a number of other possibilities, including that ratio of 
subunits (MRPP1:MRPP2:MRPP3 ratio at 2:4:1) in these experiments is not 
optimal and/or additional cofactors, such as SAM or NAD+ are required to see 
activation.  Human mtRNase P activity has not yet been shown to correlate with 
the precise subunit stoichiometry and the effect of cofactors on activity have also 
not been explored.  Hence, we propose to: 
(1) Investigate the stoichiometry of the active mtRNase P complex by measuring 
the (mt)pre-tRNATyr cleavage under single (limiting substrate; kSS and K1/2) 
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and multiple turnover (excess substrate; kcat, KM, kcat/KM) conditions as a 
function of the subunit molar ratios (e.g. each subunit alone, 1:1:1, 1:4:1, 
2:4:1, 2:2:2) and NaCl concentration.  
(2) Measure the dependence of (mt)pre-tRNATyr cleavage rate on enzyme 
concentration after the optimal ratio of MRPP1:MRPP2:MRPP3 is established. 
In the presence of 1 mM Mg2+ ions, the observed cleavage rate, kobs is 
linearly dependent on MRPP3 concentration, with kmax/K1/2 of 0.003 ± 0.0001 
min-1nM-1. The linear dependence of kobs on MRPP3 concentration suggests 
that the binding affinity of (mt)pre-tRNATyr is in the µM range (scheme 1 and 
eq. 1). If the other subunits (MRPP1/MRPP2/MRPP3) enhance pre-tRNA 
affinity, then a hyperbolic dependence on the enzyme concentration should 
be observed under single turnover conditions, assuming that kmax < k-1. This 
result would imply that the MRPP1 and MRPP2 contribute to human 
mtRNase P substrate recognition. 
 
Scheme 1   
 
Equation 1    
kobs =
kmax +[E]
K1/2 +[E] ; 
K1/2 =
kmax + k!1
k1  
(3) measure the (mt)pre-tRNATyr cleavage by MRPP1:MRPP2:MRPP3 complex 
in the presence of SAM and NAD+ cofactors. If the SAM and NAD+ is 
essential in the mtRNase P catalysis, addition of SAM and NAD+ cofactors to 
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the MRPP1:MRPP2:MRPP3 complex will enhance the cleavage rate of the 
(mt)pre-tRNATyr.  
 
Analyzing molecular recognition of human (mt)pre-tRNA 
The secondary structure of all characterized tRNAs have a cloverleaf-shape, 
including an acceptor stem, D-stem/loop, T-stem/loop, and anticodon stem/loop  
(Figure 1-7) (25,26). Unlike the canonical nuclear tRNAs, (mt)tRNAs have non-
canonical features, such as shortened or deleted stems and loops (27,28). There 
are only 22 (mt)tRNAs in the human mitochondrial genome and the (mt)pre-
tRNAs features important for mtRNase P recognition are unknown. All three 
subunits, MRPP1, MRPP2 and MRPP3 have been proposed to contribute to 
human mtRNase P substrate recognition. The MRPP2 has a Rossmann NAD+-
binding fold that has been suggested to function as an RNA binding domain, 
while MRPP1 and MRPP3 have domains that have homology to RNA binding 
proteins (29-32). Furthermore, point mutations in human (mt)tRNAs have been 
linked to human mitochondrial dysfunction, such as mitochondrial myopathy, 
encephalopathy, lactic acidosis and stroke (MELAS) syndrome (33,34). ≥ 50% of 
point mutations in tRNAIle, tRNALeu, and tRNALys have been identified to 
associate with the pathogenic diseases and are known as pathogenic mutation. 
Furthermore, pathogenic mutations in (mt)pre-tRNALeu decrease the cleavage 
efficiency of human mtRNase P (35).  Hence, we will investigate the (mt)pre-
tRNA features that are crucial for human (mt)RNase P recognition and examine 
whether pathogenic mutations in (mt)pre-tRNAs perturb mtRNase P-catalyzed 5’ 
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end maturation. We propose to: 
(1) Identify regions of (mt)pre-tRNA that bind to human mtRNase P by 
hydroxyl radical footprinting. Regions of the (mt)pre-tRNA backbone that 
contact the human mtRNase P will be protected from reaction with 
hydroxyl radicals generated from Fe-EDTA-catalyzed Fenton chemistry 
(36). The products of hydroxyl radical cleavage in the presence and 
absence of human mtRNase P will be compared and analyzed by PAGE. 
A decrease in cleavage by hydroxyl radicals will reduce the intensity of 
electrophoresis band for enzyme-substrate complex relative to the 
substrate alone. These results will allow us to compare the regions of pre-
tRNA that are protected by binding to human mtRNase P complex. 
(2) Determine specific regions of (mt)pre-tRNA that contact particular human 
mtRNase P subunits. Crosslinking experiments will be performed between 
human mtRNase P and (mt)pre-tRNATyr with 4-thiouridine (4-thioU) 
incorporated at discrete positions, including the 5’ leader, acceptor stem, 
D-stem loop, anticodon stem, and/or T-stem loop, as suggested by 
hydroxyl-radical footprinting data. 4-thioU is a photoreactive uridine analog 
that readily forms short-range RNA-RNA and RNA-protein crosslinks (37-
39). To incorporate 4-thioU into the (mt)pre-tRNATyr, chemically 
synthesized oligonucleotide containing 4-thioU will be ligated to the rest of 
the pre-tRNA prepared by in vitro transcription. Crosslinking will be 
initiated by UV irradiation (λ = 300 nm) of the mtRNase P•pre-tRNA 
complex and the crosslinked products will be isolated on a PAGE gel and 
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identified by mass spectrometry (MRPP1 ~49 kDa, MRPP2 ~26 kDa, 
MRPP3 ~65 kDa) after treatment with RNase. An alternative photoactive 
group, azidophenacyl can be used if no crosslinks are observed with 4-
thioU-labeled pre-tRNA (40).  
(3) Investigate the effect of (mt)tRNA pathogenic mutations on the efficiency 
of processing catalyzed by human mtRNase P. (mt)tRNAIle has one of the 
highest number of pathogenic mutations among the (mt)tRNAs. Therefore, 
(mt)pre-tRNAIle with 3’ trailers will be prepared by site-directed 
mutagenesis with the following nucleotide substitutions: A7G, U12C, 
U27C, G40A, G51A, A59G, C62U. Single and multiple turnover 
parameters for cleavage of (mt)pre-tRNAIle catalyzed by human mtRNase 
P will be measured to evaluate the effect of these mutants on the (mt)pre-
tRNA processing. The cleavage site selection of (mt)pre-tRNAIle mutants 
will also be determined from the mobility of the 5′ cleavage products, as 
described (41). 
The future studies proposed in this chapter will elucidate the role of each MRPP 
subunit in mtRNase P catalysis, identify the binding sites for metal ions that 
activate human mtRNase P and determine the essential features of (mt)pre-tRNA 
for human mtRNase P recognition. These studies will provide insight into how the 
mechanism of this enzyme and into how a “proteinaceous” RNase P could evolve 
to adopt the functionality and molecular recognition of a RNA-mediated RNase P. 
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